

CITATION REPORT

List of articles citing

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

DOI: 10.1200/jco.2006.06.4451

Journal of Clinical Oncology, 2006, 24, 3187-205.

Source: <https://exaly.com/paper-pdf/40605717/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1452	Filgrastim XM02 (Tevagrastim [®]) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. 2013 , 7, 327		10
1451	New horizons for gastric cancer: commentary. 2006 , 4, 1-3		
1450	The role of docetaxel in gastric cancer. 2006 , 4, 4-9		1
1449	Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice. 2006 , 3, 530-536		10
1448	Treating elderly cancer patients: what you need to know about their physiology and specific medical needs. 2006 , 3, 730-734		
1447	Recent Publications on Medications and Pharmacy. 2006 , 41, 899-904		
1446	Docetaxel and Cisplatin (DP) Regimen for Solid Tumors. 2006 , 41, 1032-1042		
1445	Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC Followed by D) in the Treatment of Breast Cancer. 2006 , 41, 1156-1163		
1444	The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice. 2006 , 10, 22-31		
1443	Neutropenia: etiology and pathogenesis. 2006 , 8 Suppl 5, S5-11		43
1442	Risks and consequences of chemotherapy-induced neutropenia. 2006 , 8 Suppl 5, S12-8		25
1441	An analysis of current neutropenia therapies, including pegfilgrastim. 2006 , 8 Suppl 5, S19-28		11
1440	Docetaxel âmaximising outcomes towards cure in early breast cancer. 2006 , 15, S13-S16		2
1439	Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. 2006 , 2, 667-76		1
1438	Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5207-15	2.2	90
1437	When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2975-7	2.2	18
1436	Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?. 2006 , 17, 1181-3		4

1435	Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5615-6; author reply 5616	2.2	2
1434	In Reply. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5614-5614	2.2	1
1433	Neutropenia: state of the knowledge part I. 2006 , 33, 1193-201		15
1432	In Reply. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2491-2493	2.2	4
1431	Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. <i>Oncologist</i> , 2007 , 12, 1019-26	5.7	47
1430	Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. <i>Oncologist</i> , 2007 , 12, 484-94	5.7	41
1429	Immunomodulatory therapy in yeast infections. 2007 , 5, 129-40		3
1428	Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. 2007 , 41, 1531-5		15
1427	ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. 2007 , 18, 376-80		52
1426	XXII Congresso de Pneumologia Estoril, 8 a 10 de Dezembro de 2006. 2007 , 13 Suppl 3, S163-80		
1425	[S3-Guidelines "Exocrine pancreatic cancer" 2007]. <i>Zeitschrift Fur Gastroenterologie</i> , 2007 , 45, 487-523	1.6	102
1424	In Reply. <i>Oncologist</i> , 2007 , 12, 1465-1466	5.7	1
1423	Pegfilgrastim-induced hyperleukocytosis. 2007 , 41, 1524-30		11
1422	Hematopoietic growth factors: ESMO recommendations for the application. 2007 , 18 Suppl 2, ii89-91		12
1421	Geriatric oncology: a field coming of age. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1821-3	2.2	66
1420	Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors. 2007 , 34, 347-53		5
1419	Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. 2007 , 41, 1648-59		32
1418	Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. <i>Oncologist</i> , 2007 , 12 Suppl 2, 7-13	5.7	49

1417	Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. 2007 , 109, 3424-31	76
1416	Cancer Chemotherapy Update - Cisplatin, Doxorubicin, and High-dose Methotrexate for Osteosarcoma. 2007 , 42, 702-710	
1415	Granulocyte colony-stimulating factors: finding the right indication. 2007 , 19, 299-307	22
1414	Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. 2007 , 19, 328-35	26
1413	Future of geriatric oncology. 2007 , 3, 149-158	4
1412	Neutrophils febriles. 2007 , 2, 1-5	
1411	Breast cancer and pregnancy. 2007 , 10,	
1410	Mastering chemotherapy dose reduction in elderly cancer patients. 2007 , 43, 2235-41	29
1409	Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. 2007 , 43, 2345-50	19
1408	Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. 2007 , 44, 148-56	27
1407	Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. 2007 , 44, 183-92	19
1406	Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. 2007 , 44, 203-11	14
1405	Hematopoietic growth factors in the treatment of acquired bone marrow failure states. 2007 , 44, 138-47	40
1404	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. 2007 , 8, 1101-1115	270
1403	Fever of unknown origin in febrile leukopenia. 2007 , 21, 1055-90, x	27
1402	Topotecan in the management of cervical cancer. 2007 , 8, 227-36	11
1401	Agents under investigation for the treatment and prevention of neutropenia. 2007 , 16, 1831-40	6
1400	Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. 2007 , 25, 343-51	23

1399	Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. 2007 , 48, 570-6		48
1398	Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3158-67	2.2	522
1397	Adjuvant chemotherapy for early-stage breast cancer. 2007 , 21, 207-22		1
1396	Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. 2007 , 23, 2283-95		127
1395	International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1832-43	2.2	180
1394	Neutropenias febriles. 2007 , 11, 1-5		
1393	Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. 2007 , 6, 367-73		17
1392	Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. 2007 , 7, 413-20		8
1391	Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas. 2007 , 8 Suppl 2, S50-6		1
1390	Non-chemotherapy drug-induced agranulocytosis. 2007 , 6, 323-35		39
1389	Cancer Chemotherapy Update: Mesna, Doxorubicin, Ifosfamide, and Dacarbazine (MAID) Regimen for Sarcomas. 2007 , 42, 901-906		1
1388	Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. 2007 , 13, 337-48		89
1387	Doxorubicin, Cisplatin, High-dose Methotrexate, and Ifosfamide for Osteosarcoma. 2007 , 42, 801-811		1
1386	Myeloid growth factor therapy for prophylaxis of febrile neutropenia in non-myeloid malignancies: appropriate doses and schedules. 2007 , 5, 229-34		
1385	Docetaxel and Carboplatin (DC) for Solid Tumors. 2007 , 42, 27-33		
1384	Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone (EPOCH) for Treatment of Lymphomas. 2007 , 42, 1006-1012		
1383	Docetaxel and Capecitabine (DC) Regimen for Solid Tumors. 2007 , 42, 191-196		
1382	Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. 2007 , 109, 939-48		43

1381	Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 2007 , 110, 1611-20	99
1380	Peg-filgrastim versus filgrastim after autologous stem cell transplantation: case-control study in patients with multiple myeloma and review of the literature. 2007 , 31, 1487-93	13
1379	Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma. <i>Bone Marrow Transplantation</i> , 2007 , 40, 1147-55	4-4
1378	Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. 2007 , 97, 162-9	140
1377	Does chemotherapy-induced neutropenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. 2007 , 97, 1642-7	8
1376	Chemotherapy for older patients with prostate cancer. 2007 , 99, 269-73	18
1375	Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. 2007 , 137, 436-42	5
1374	Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. 2007 , 138, 146-52	13
1373	Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. 2007 , 17, 1019-24	13
1372	Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer. 2007 , 8 Suppl 1, S11-21	5
1371	Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. 2007 , 7, 77	16
1370	Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. 2007 , 106, 342-7	13
1369	Erythropoietin after a century of research: younger than ever. 2007 , 78, 183-205	292
1368	[Dose intensity received in breast cancer treatment with chemotherapy]. 2007 , 31, 270-5	3
1367	Neutropenic enterocolitis in children with acute leukemia or aplastic anemia. 2007 , 86, 364-8	18
1366	Prise en charge des lymphomes chez les personnes âgées. 2007 , 9, 214-218	
1365	Les soins de support génèrent des effets indésirables. Paradigmes à résoudre Primum non nocere.... 2007 , 9, HS41-HS46	
1364	Spécificité de la chimiothérapie chez le sujet âgé. 2007 , 9, 783-789	

1363	Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. 2007 , 64, 64-72		32
1362	Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. 2007 , 63, 53-64		20
1361	A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. 2008 , 109, 343-50		36
1360	Symptomkontrolle und spezielle Betreuung in der medizinischen Onkologie. 2008 , 41, 593-596		
1359	[Supportive care for malignant melanoma]. 2008 , 59, 492-8		1
1358	Leukopenie. 2008 , 3, 161-178		0
1357	Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. 2008 , 9, 191-203		44
1356	Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes. 2008 , 10, 412-9		4
1355	Bertherapie in der Onkologie: Wann ist weniger mehr?. 2008 , 14, 691-700		3
1354	Recommandations pour lâ'utilisation des facteurs de croissance granulocytaires en oncologie. 2008 , 10, 310-315		2
1353	[Individualized management and therapy of myelodysplastic syndromes]. 2008 , 120, 523-37		5
1352	Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. <i>Supportive Care in Cancer</i> , 2008 , 16, 181-91	3.9	30
1351	Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern. <i>Supportive Care in Cancer</i> , 2008 , 16, 1085-8	3.9	38
1350	Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. <i>Supportive Care in Cancer</i> , 2008 , 16, 1299-309	3.9	105
1349	Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. 2008 , 112, 2671-5		27
1348	Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. 2008 , 113, 945-55		55
1347	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. 2008 , 26, 247-51		34
1346	Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. 2008 , 22, 221-34		36

1345	New emerging applications of molgramostim in acute myeloid leukaemia. 2008 , 4, 795-806	3
1344	Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. <i>Bone Marrow Transplantation</i> , 2008 , 42, 507-13	4-4 7
1343	Renal function as a predictor of irinotecan-induced neutropenia. 2008 , 84, 254-62	30
1342	Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. 2008 , 30, 292-9	7
1341	Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. 2008 , 11, 172-9	61
1340	Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. 2008 , 48, 640-6	4
1339	Management of leukopenia in kidney and pancreas transplant recipients. 2008 , 22, 822-8	40
1338	Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. 2008 , 110, 329-35	21
1337	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. 2008 , 8, 195	36
1336	XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. 2008 , 8, 332	83
1335	Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). 2008 , 61, 405-15	56
1334	[GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients]. 2008 , 130, 300-11	6
1333	Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim. 2008 , 4, e40	
1332	Managing myelotoxicities of breast cancer chemotherapies: what is the role for G-CSF?. 2008 , 6, 17-23	
1331	Managing the myelotoxicity of CHOP chemotherapy. 2008 , 6, 31-36	1
1330	S3-Guideline "Exocrine Pancreatic Carcinoma" 2007. <i>Zeitschrift Fur Gastroenterologie</i> , 2008 , 46, 449-482 1.6	3
1329	Breast Cancer 2nd edition. 2008 ,	1
1328	Chemotherapy for Breast Cancer. 2008 , 345-385	1

1327	Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. 2008 , CD003189	63
1326	Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. 2008 , 44, 182-94	86
1325	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. 2008 , 44, 353-65	16
1324	Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses. 2008 , 12, 14-25	6
1323	Variation in supportive care practices in hematopoietic cell transplantation. 2008 , 14, 1231-8	44
1322	Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. 2008 , 8, 993-1001	19
1321	Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. 2008 , 9, 269-78	43
1320	Administration du traitement médical en pratique (y compris facteurs de croissance). 2008 , 25, 3S151-3S159	
1319	[Fever and infectious complications in patient with lung cancer]. 2008 , 64, 99-103	1
1318	Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. 2008 , 49, 1530-6	9
1317	Current treatment options and strategies for myelodysplastic syndromes. 2008 , 9, 1667-78	3
1316	Evaluaci3n econ3mica del uso de pegfilgrastim frente a filgrastim en profilaxis primaria en pacientes con c3ncer de mama con riesgo de padecer neutropenia febril en Espaã. 2008 , 5, 71-81	1
1315	Evolving strategies in the management of aspergillosis. 2008 , 9, 193-209	9
1314	Common acute oncological emergencies: diagnosis, investigation and management. 2008 , 84, 418-27	23
1313	Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. 2008 , 65, 1552-5	12
1312	Rheumatic Manifestations in Malignancy. 2008 , 4, 50-58	1
1311	The role of chemotherapy at the end of life: "when is enough, enough?". 2008 , 299, 2667-78	197
1310	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. 2008 , 9, 1885-93	2

1309	Caring for the treatment-experienced breast cancer patient: the pharmacist's role. 2008 , 65, S16-22	9
1308	Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. 2008 , 14, 3889-95	34
1307	Safety of pegfilgrastim in children. 2008 , 42, 290	3
1306	Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 290-6	2.2 24
1305	The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. 2008 , 14, 131-8	6
1304	Granulocyte colony-stimulating factor (G-CSF) in the mechanism of human ovulation and its clinical usefulness. 2008 , 15, 604-13	34
1303	Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. 2008 , 12, 13-20	14
1302	Hematopoietic growth factors: ESMO recommendations for the applications. 2008 , 19 Suppl 2, ii116-8	22
1301	Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling. 2008 , 14, 6354-63	22
1300	Cancer Supportive Care. 2008 ,	1
1299	The influence of mucositis on oral thermometry: when fever may not reflect infection. 2008 , 46, 1859-63	17
1298	Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. 2008 , 19, 292-8	114
1297	Cost of neutropenic complications of chemotherapy. 2008 , 19, 454-60	62
1296	Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. 2008 , 4, 199-210	2
1295	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. 2008 , 19, 853-60	40
1294	Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. 2008 , 3, 623-30	162
1293	Prophylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. 2008 ,	1
1292	Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. 2008 , 3, 1018-25	2

1291	Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 2008 , 6, 109-18	173
1290	The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. 2008 , 3, 145-51	12
1289	Undertreatment of cancer patients with chemotherapy is a global concern. 2008 , 4, 114-5	7
1288	Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. 2008 , 31, 369-74	28
1287	Challenges in surgical management of abdominal pain in the neutropenic cancer patient. 2008 , 248, 104-9	46
1286	Practical issues in cytotoxic chemotherapy usage. 1-12	
1285	Clinical uses of GM-CSF, a critical appraisal and update. 2008 , 2, 13-27	48
1284	Cyclophosphamide, Vincristine, Doxorubicin and Dacarbazine (CYVADIC) for Soft Tissue Sarcomas. 2008 , 43, 18-28	
1283	Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) for Breast Cancer. 2008 , 43, 462-468	1
1282	Irinotecan and Cisplatin (IP) Regimen. 2008 , 43, 970-975	1
1281	Ifosfamide, Carboplatin, and Etoposide (ICE) for Metastatic Soft Tissue Sarcoma. 2008 , 43, 878-882	
1280	IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients. 2008 , 94, 96-109	10
1279	Management of Chemotherapy-Induced Neutropenia: Opportunities for Pharmacist Involvement. 2008 , 43, 472-484	
1278	Current optimal chemotherapy for advanced urothelial cancer. 2008 , 8, 51-61	5
1277	Critically Ill Immunosuppressed Host. 2008 , 1111-1132	
1276	Docetaxel, Cisplatin, and Fluorouracil (DCF) Regimen for Head, Neck, and Advanced Gastric Cancers. 2008 , 43, 266-276	1
1275	Cisplatin and Pemetrexed for Lung Cancer and Pleural Mesothelioma. 2008 , 43, 800-805	
1274	Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Regimen. 2008 , 43, 556-560	

- 1273 Gemcitabine and Docetaxel (GD) for Advanced Soft Tissue Sarcomas. **2008**, 43, 187-191
- 1272 Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. **2009**, 3, 241-52 5
- 1271 Docetaxel and Estramustine for Prostate Cancer. **2009**, 44, 473-478
- 1270 BEACOPP(escalated) Regimen for Hodgkin Lymphoma. **2009**, 44, 858-865
- 1269 Delivery of chemotherapy at planned dose and on time. **2009**, 8, 16-19 5
- 1268 Relative dose intensity delivered to patients with early breast cancer: Canadian experience. **2009**, 16, 8-12 30
- 1267 BEACOPP(baseline) Regimen for Hodgkin Lymphoma. **2009**, 44, 662-669 1
- 1266 [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy]. **2009**, 96, 1013-28 6
- 1265 Fluorouracil, Epirubicin, and Cyclophosphamide (FEC100) for Breast Cancer. **2009**, 44, 26-31 3
- 1264 Melphalan, Prednisone, and Thalidomide (MPT) Regimen for Multiple Myeloma. **2009**, 44, 569-573
- 1263 Gemcitabine and Capecitabine (GemCap) Regimen for Solid Tumors. **2009**, 44, 303-309
- 1262 Irinotecan and Carboplatin (IC) Regimen for Lung Cancer. **2009**, 44, 740-745
- 1261 Pemetrexed and Carboplatin (PC) Regimen. **2009**, 44, 946-951
- 1260 Cost-Effectiveness of Pegfilgrastim versus Six Days of Filgrastim for Preventing Febrile Neutropenia in Breast Cancer Patients. **2009**, 95, 219-226 31
- 1259 Medical Problems and Radiotherapy Emergencies. 122-138
- 1258 Variant neutropenic enterocolitis presenting as acute appendicitis. **2009**, 10, 301-5 3
- 1257 Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. **2009**, 11, 825-32 55
- 1256 Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. **2009**, 25, 1455-60 11

1255	Breast cancer: Improved care through effective management of febrile neutropenia. Foreword. 2009 , 101 Suppl 1, S1		1
1254	Management of chemotherapy-associated febrile neutropenia. 2009 , 101 Suppl 1, S18-22		36
1253	Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. 2009 , 101 Suppl 1, S15-7		12
1252	Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. 2009 , 15, 745-53		44
1251	Hematopoietic growth factors in pediatric patients. 2009 , 30, 30-1		1
1250	Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy. 2009 , 20, 795-6		3
1249	A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. 2009 , 20, 513-9		50
1248	Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. 2009 , 15, 7361-7		30
1247	A health services research agenda for cellular, molecular and genomic technologies in cancer care. 2009 , 12, 233-44		14
1246	The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools. 2009 , 4, 167-176		4
1245	Adjuvant systemic therapy for older adults with early-stage breast cancer. 2009 , 5, 251-62		3
1244	Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. 2009 , 20, 34-40		39
1243	Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma. <i>Expert Review of Hematology</i> , 2009 , 2, 159-72	2.8	1
1242	Hematopoietic growth factors: ESMO recommendations for the applications. 2009 , 20 Suppl 4, 162-5		15
1241	The transplant pharmacopeia. 2009 , 331-342		
1240	Proactive management of adverse events maintains the clinical benefit of ixabepilone. <i>Oncologist</i> , 2009 , 14, 448-55	5.7	14
1239	Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose. 2009 , 43, 235-41		12
1238	The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. 2009 , 63 Suppl 1, i36-40		26

1237	Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells. 2009 , 135, 44-50		12
1236	The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. 2009 , 112, 601-4		30
1235	An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. 2009 , 113, 63-7		18
1234	Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. 2009 , 31, 1092-104		54
1233	Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. 2009 , 31, 1069-81		58
1232	Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. 2009 , 31 Pt 2, 2388-95		12
1231	Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. 2009 , 115, 4839-48		30
1230	Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery. 2009 , 76, 328-33		4
1229	The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience. <i>Supportive Care in Cancer</i> , 2009 , 17, 471-8	3-9	3
1228	Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. <i>Supportive Care in Cancer</i> , 2009 , 17, 735-44	3-9	3
1227	Breast conserving treatment (BCT) for stage I-II breast cancer in elderly women: analysis of 927 cases. 2009 , 71, 79-88		18
1226	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. 2009 , 72, 21-44		17
1225	Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. 2009 , 72, 170-9		33
1224	Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint. 2009 , 168, 283-97		33
1223	Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. 2009 , 114, 579-87		15
1222	Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. 2009 , 11, 446-54		4
1221	Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. 2009 , 90, 191-198		8
1220	Supportivtherapie in der Onkologie. <i>Best Practice Onkologie</i> , 2009 , 4, 42-52		0

1219	Geriatrische Onkologie. <i>Best Practice Onkologie</i> , 2009 , 4, 46-54		0
1218	[Supportive therapy of urogenital tumors: diagnostic and therapy of common complications]. <i>Der Urologe</i> , 2009 , 48, 1273-4, 1276-8, 1280-2		
1217	Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 2009 , 88, 97-110		107
1216	Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 509-16	3.5	9
1215	Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 877-83	3.5	16
1214	Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 129-36	3.5	14
1213	A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. 2009 , 9, 2		5
1212	Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. 2009 , 144, 677-85		75
1211	Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study. 2009 , 18, 280-6		48
1210	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. 2009 , 23, 1118-26		87
1209	Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. <i>Bone Marrow Transplantation</i> , 2009 , 43, 351-6	4.4	21
1208	Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 669-77	4.4	25
1207	Optimal use of G-CSF administration after hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 895-908	4.4	46
1206	The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. 2009 , 100, 436-41		17
1205	Chemotherapy for early-stage breast cancer: a brief history. 2009 , 101 Suppl 1, S2-5		22
1204	Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. 2009 , 101 Suppl 1, S6-10		33
1203	Impact of effective prevention and management of febrile neutropenia. 2009 , 101 Suppl 1, S23-6		27
1202	Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients--the Hong Kong experience. 2009 , 5, 123-128		3

1201	Are guidelines on use of colony-stimulating factors in solid cancers flawed?. 2009 , 39, 259-62	3
1200	Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly. 2009 , 9, 115-23	4
1199	Neoadjuvant systemic therapy for urological malignancies. 2010 , 106, 6-22	21
1198	The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. 2009 , 12, 20-7	66
1197	Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. 2009 , 12, 217-25	41
1196	Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. 2009 , 12, 481-8	18
1195	Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. 2009 , 72, 144-54	38
1194	Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. 2009 , 72, 265-9	8
1193	Recent developments in the treatment of aggressive non-Hodgkin lymphoma. 2009 , 23, 11-23	22
1192	G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. 2009 , 5, 554-9	121
1191	Neutropenic enterocolitis. 2009 , 10, 307-14	45
1190	Granulocyte colony-stimulating factor: biology and clinical potential. 2009 , 569-580	
1189	PEG conjugates in clinical development or use as anticancer agents: an overview. 2009 , 61, 1177-88	380
1188	Short telomeres are sufficient to cause the degenerative defects associated with aging. 2009 , 85, 823-32	178
1187	Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. 2009 , 28, 181-4	4
1186	Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. 2009 , 20, 271-81	48
1185	Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. 2009 , 45, 608-17	55
1184	Docetaxel-related side effects and their management. 2009 , 13, 49-59	160

1183	Cancer chemotherapy in the older cancer patient. 2009 , 27, 633-42	22
1182	Outpatient management of low-risk febrile patients on paclitaxel and carboplatin for ovarian cancer. 2009 , 105, 261-2	
1181	Aspergillosis. 2009 , 360, 1870-84	527
1180	Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. 2009 , 66, 327-32	9
1179	Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. 2009 , 24, 122-9	23
1178	Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. 2009 , 29, 491-513	6
1177	Cisplatin overdose: toxicities and management. 2009 , 32, 1109-22	139
1176	Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?. 2009 , 69, 1727-37	1
1175	Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. 2009 , CD007107	38
1174	Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. 2009 , 28, 116	48
1173	Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. 2009 ,	15
1172	Management of head and neck cancer in elderly patients. 2009 , 26, 571-83	22
1171	History and development of radiation-protective agents. 2009 , 85, 539-73	199
1170	Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia?. 2009 , 50, 1872-4	4
1169	XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. 2009 , 50, 374-9	56
1168	Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. 2009 , 25, 2533-42	39
1167	The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. 2009 , 7, 193-205	34
1166	Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. 2009 , 23, 175-86	43

1165	Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. 2009 , 25, 401-11	49
1164	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. 2009 , 10, 785-93	81
1163	Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. 2009 , 373, 226-33	115
1162	Manejo general y extrahospitalario del paciente en tratamiento con quimioterapia y de sus complicaciones. 2009 , 10, 1613-1618	
1161	Protocolo diagnóstico y terapéutico de la neutropenia febril. 2009 , 10, 1619-1621	
1160	Les facteurs de croissance hématoïologique en cancérologie thoracique. 2009 , 1, 314-319	
1159	Cas clinique n°2 proposé par l'équipe de Strasbourg. 2009 , 65, 8-13	
1158	Fever and neutropenia in pediatric patients with cancer. 2009 , 27, 525-44	40
1157	The role of the primary care physician during the active treatment phase. 2009 , 36, 685-702	5
1156	Supportive care in elderly cancer patients. 2009 , 21, 310-7	26
1155	Advances in the treatment of neutropenia. 2009 , 3, 207-12	17
1154	Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?. 2009 , 21, 297-302	14
1153	Neutrophil biology and the next generation of myeloid growth factors. 2009 , 7, 92-8	5
1152	Impact of chemotherapy dose intensity on cancer patient outcomes. 2009 , 7, 99-108	200
1151	The role of myeloid growth factors in acute leukemia. 2009 , 7, 84-91	9
1150	Drugs that act on the immune system: cytokines and monoclonal antibodies. 2009 , 589-618	
1149	Hematopoietic Growth Factors (Cytokines). 498-507	
1148	Myeloid growth factors. 2009 , 7, 64-83	44

1147	Inductive potential of recombinant human granulocyte colony-stimulating factor to mature neutrophils from x-irradiated human peripheral blood hematopoietic progenitor cells. 2009 , 32, 1849-53	5
1146	Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. 2009 , 19, 447-54	4
1145	Colony-stimulating factors for the prevention of chemotherapy induced febrile neutropenia in breast cancer patients. 2009 ,	1
1144	Update on MDS therapy: from famine to feast. 2010 , 8, 187-98	
1143	[Febrile neutropenia in adult patients with solid tumours: a review of literature toward a rational and optimal management]. 2010 , 97, 547-57	5
1142	Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. 2010 , 21, 306-12	1
1141	Rationale and recommendations for treatment of radiation injury with cytokines. 2010 , 98, 838-42	30
1140	Standards for palliative care delivery in oncology settings. 2010 , 16, 436-43	8
1139	Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia. 2010 , 37, 765-73	16
1138	Benefits of a network approach to managing neutropenic sepsis. 2010 , 9, 17-21	3
1137	Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). 2010 , 116, 2026-32	43
1136	The role of colony stimulating factors administered for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 2010 ,	
1135	Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer. 2010 , 5, 837-40	6
1134	Improving Insulin Distribution and Administration Safety Using Lean Six Sigma Methodologies. 2010 , 45, 212-224	9
1133	Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience. 2010 , 5, 667-72	5
1132	Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2914-24	2.2 143
1131	Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. 2010 , 89, 897-904	56
1130	Sequential versus simultaneous use of vinorelbine and capecitabine at the same dosage as first-line chemotherapy for patients with metastatic breast cancer. 2010 , 9, 528-535	2

1129 Therapiestrategien für die Behandlung des Hodgkin-Lymphoms bei älteren Patienten. **2010**, 16, 55-62

1128 Supportive Therapie bei multiplem Myelom. **2010**, 16, 298-308

1127 [Comorbidity oriented oncology - an overview]. **2010**, 122, 203-18

2

1126 Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting. **2010**, 122, 649-52

1125 Implementation of a pharmacist-initiated pharmaceutical handover for oncology and haematology patients being transferred to critical care units. *Supportive Care in Cancer*, **2010**, 18, 811-6

3.9 19

1124 Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. *Supportive Care in Cancer*, **2010**, 18, 529-41

3.9 71

1123 Very low rates of neutropenic complications and chemotherapy dose modifications in early breast cancer patients receiving adjuvant FEC-100 or TAC and an individualised G-CSF and anti-infective support: results of a retrospective chart review. **2010**, 3, 123-128

1122 Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation. **2010**, 4, 1-7

10

1121 Supportive care for patients with early breast cancer. **2010**, 12, 32-42

2

1120 Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. **2010**, 122, 787-94

10

1119 [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors]. **2010**, 34 Suppl 1, 8-11

1118 The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. **2010**, 10, 642

18

1117 Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. **2010**, 32, 311-26

11

1116 Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. **2010**, 116, 5279-89

15

1115 VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. **2010**, 51, 209-15

6

1114 Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. **2010**, 74, 203-10

26

1113 Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies. **2010**, 54, 134-7

10

1112 Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF. **2010**, 54, 728-33

3

1111	Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. 2010 , 50, 2432-46		11
1110	Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. 2010 , 58, 1885-95		17
1109	Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. 2010 , 149, 693-705		170
1108	Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. 2010 , 19, 200-4		8
1107	Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. 2010 , 19, 648-55		26
1106	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. 2010 , 103, 315-23		8
1105	Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. <i>Bone Marrow Transplantation</i> , 2010 , 45, 277-81	4.4	21
1104	Surrogate end-points in clinical practice: are we providing worse care?. 2010 , 40, 395-8		4
1103	Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers. 2010 , 36, 764-8		4
1102	Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. 2010 , 17, 2-3		31
1101	Management of non-Hodgkin's lymphoma in older adults. 274-287		
1100	The myeloid growth factors in older adults with cancer. 323-337		
1099	Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. 2010 , 13, 615-25		25
1098	Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. 2010 , 16, 242-50		59
1097	Bortezomib and Dexamethasone (BD) Regimen for Multiple Myeloma. 2010 , 45, 33-37		
1096	Ondansetron: Tardive Dyskinesia. 2010 , 45, 301-302		
1095	Docetaxel and Prednisone (DP) for Advanced Prostate Cancer. 2010 , 45, 293-302		
1094	Neutropenia Following Induction Therapy in acute Myeloid Leukaemia (AML) and Role of Granulocyte colony stimulating factor (G-CSF). 2010 , 18, 155-160		

1093	Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. 2011 , 157, 145-65		6
1092	Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. 2010 , 21, 1482-1485		16
1091	Management of Antimicrobials in Infectious Diseases. 2010 ,		5
1090	Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. 2010 , 70, 936-47		64
1089	Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope. <i>Journal of Clinical Oncology</i> , 2010 , 28, 523-6	2.2	12
1088	Managing Infections in Patients With Hematological Malignancies. 2010 ,		1
1087	Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3323-9	2.2	423
1086	Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. 2010 , 13, 815-8		10
1085	Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. 2010 , 7, 187-201		13
1084	Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2598-603	2.2	101
1083	Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. 2010 , 10, 615-30		7
1082	Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX) Regimens plus Bevacizumab for Colorectal Cancer. 2010 , 45, 685-693		
1081	Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. 2010 , 6, 133-40		63
1080	How we treat febrile neutropenia in patients receiving cancer chemotherapy. 2010 , 6, 149-52		26
1079	Docetaxel, Cisplatin, and Fluorouracil (TCF) for Head and Neck Cancers. 2010 , 45, 453-460		
1078	Epirubicin, Cisplatin, and Capecitabine (ECX) Regimen. 2010 , 45, 527-533		
1077	Lapatinib and Capecitabine. 2010 , 45, 762-767		
1076	Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. 2010 , 2010, 692097		20

1075	Docetaxel and Carboplatin (DC) for Ovarian Cancer. 2010 , 45, 607-613	
1074	Using a computer-based risk assessment tool to identify risk for chemotherapy-induced febrile neutropenia. 2010 , 14, 87-91	3
1073	Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. 2010 , 14, 81-6	12
1072	Pemetrexed safety and pharmacokinetics in patients with third-space fluid. 2010 , 16, 2872-80	19
1071	Stanford V Regimen for Hodgkin Lymphoma. 2010 , 45, 906-913	
1070	Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. 2010 , 21 Suppl 5, v248-51	155
1069	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. 2010 , 64 Suppl 2, e1-164	85
1068	Overview of aggressive lymphomas in the older adult. 2010 , 6, 191-200	
1067	Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. 2010 , 79, 93-7	6
1066	[Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. 2010 , 97, 265-80	2
1065	Prise en charge des neutrophies fébriles au cours du cancer bronchique. 2010 , 2, 252-258	
1064	[Clinical case No. 1 proposed by the E Quoix (CHRU Strasbourg) team]. 2010 , 66, H3-8	
1063	Diagnosis and management of infectious complications in critically ill patients with cancer. 2010 , 26, 59-91	54
1062	Managing fungal and viral infections in pediatric leukemia. <i>Expert Review of Hematology</i> , 2010 , 3, 603-242.8	1
1061	[Spanish Paediatric Infectious Diseases Society consensus document on the treatment of fungal infections based on the immune response]. 2010 , 73, 362.e1-8	
1060	The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. 2010 , 68, 403-8	6
1059	Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. 2010 , 10, 44-50	25
1058	Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1522-7	4.4 17

1057	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. 2010 , 28, 275-80		302
1056	Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance. 2010 , 1, 87-102		24
1055	Combined treatment with cytoprotective agents and radiotherapy. 2010 , 36, 268-75		24
1054	Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. 2010 , 46, 2389-98		33
1053	Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. 2010 , 8, 242-51		18
1052	Controversies in the management of fever in the neutropenic cancer patient. 2010 , 42, 151-6		1
1051	Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis. 2010 , 7, 297-308		25
1050	Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices. 2010 , 7, 273-280		3
1049	Impact of age, sex, and comorbidity on cancer therapy and disease progression. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4086-93	2.2	164
1048	Dose-dense chemotherapy for breast cancer: what does the future hold?. 2010 , 6, 951-65		7
1047	Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective. 2010 , 109, 624-31		11
1046	Pharmacokinetic study of a novel recombinant human granulocyte colony-stimulating factor in rats. 2010 , 25, 13-9		5
1045	Non-Hodgkin's lymphoma in the elderly. 2010 , 27, 211-38		7
1044	The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is 'just right'?. 2011 , 52, 548-9		3
1043	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. 2011 , 52, e56-93		1797
1042	Les traitements de soutien en cancfologie thoracique. 2011 , 3, 315-319		
1041	Essential drugs in supportive care. 2011 , 38, 413-23		0
1040	Cabazitaxel Side Effects: Prevention and Management. 2011 , 4, S21-S27		3

1039	Health care use and primary prophylaxis with colony-stimulating factors. 2011 , 14, 247-52	6
1038	Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy. 2011 , 14, 253-62	7
1037	A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. 2011 , 71, 151-5	11
1036	Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer. 2011 , 72, 224-8	5
1035	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. 2011 , 74, 75-9	14
1034	Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. 2011 , 71, 679-707	10
1033	The use of myeloid colony-stimulating factors in hematologic malignancies: the role of systematic reviews and meta-analyses. 2011 , 125, 68-79	1
1032	Immune response to <i>Aspergillus fumigatus</i> in compromised hosts: from bedside to bench. 2011 , 6, 73-83	14
1031	Testicular germ cell tumors: pathogenesis, diagnosis and treatment. 2011 , 7, 43-53	74
1030	Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. 2011 , 45, 1094-102	8
1029	Hematopoietic Growth Factors in Oncology. 2011 ,	5
1028	The MASCC Textbook of Cancer Supportive Care and Survivorship. 2011 ,	6
1027	Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis. 2011 , 313, 9-14	33
1026	[Guidelines for the treatment of invasive fungal disease by <i>Aspergillus</i> spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update]. 2011 , 29, 435-54	24
1025	Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group. 2011 , 47, 215-20	25
1024	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. 2011 , 47, 8-32	727
1023	Can G-CSF cause leukemia in hematopoietic stem cell donors?. 2011 , 17, 1739-46	30
1022	Colony-stimulating factors in the prevention and management of infectious diseases. 2011 , 25, 803-17	19

1021	Recombinant canine granulocyte colony-stimulating factor accelerates recovery from cyclophosphamide-induced neutropenia in dogs. 2011 , 142, 271-5	9
1020	Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. 2011 , 8, 311-325	2
1019	Critical Illness Involving Children Undergoing Hematopoietic Progenitor Cell Transplantation. 2011 , 1177-1190	1
1018	Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. 2011 , 51, 1-5	34
1017	Uptake of novel medical therapies in the general population. 2011 , 18, 105-8	6
1016	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Regimen for Multiple Myeloma. 2011 , 46, 839-847	
1015	Mitigation of ionizing radiation-induced bone marrow suppression by p38 inhibition and G-CSF administration. 2011 , 52, 712-6	25
1014	Filgrastim as a rescue therapy for persistent neutropenia in a case of dengue hemorrhagic Fever with acute respiratory distress syndrome and myocarditis. 2011 , 2011, 896783	3
1013	The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. 2011 , 18, e288-96	24
1012	Evaluation of current practice: management of chemotherapy-related toxicities. 2011 , 22, 919-25	12
1011	Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 2011 , 49, 649-57	14
1010	A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. 2011 , 18, 1-10	5
1009	Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. 2011 ,	0
1008	Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 2011 , CD008238	4
1007	Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. 2011 , 117, 2121-8	15
1006	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. 2011 , 118, 3426-35	50
1005	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. 2011 , 118, 3489-98	145
1004	SUPPORTIVE CARE. 2011 , 311-338	

1003	Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. 2011 , 2, 859-866	67
1002	Myeloid growth factors. 2011 , 9, 914-32	23
1001	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. 2011 , 41, 110-20	19
1000	Acute myeloid leukaemia in the elderly: a review. 2011 , 152, 524-42	108
999	How I manage haematology patients with septic shock. 2011 , 152, 380-91	9
998	Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. 2011 , 153, 773-9	29
997	Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. 2011 , 7, 75-81	16
996	A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. 2011 , 104, 407-12	13
995	Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles. 2011 , 156, 101-8	18
994	Adverse drug reactions and drug interactions as causes of hospital admission in oncology. 2011 , 42, 342-53	58
993	Management of the cancer patient with infection and neutropenia. 2011 , 38, 424-30	14
992	Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study. 2011 , 123, 360-4	11
991	Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. 2011 , 61, 287-314	57
990	A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. 2011 , 12, 161-5	6
989	Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. 2011 , 80, 466-73	24
988	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. 2011 , 12, 851-63	17
987	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. <i>Bone Marrow Transplantation</i> , 2011 , 46, 956-61	4-4 12
986	Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. 2011 , 127, 511-20	7

985	Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. 2011 , 130, 255-66		13
984	Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. <i>Supportive Care in Cancer</i> , 2011 , 19, 333-41	3.9	57
983	Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. <i>Supportive Care in Cancer</i> , 2011 , 19, 483-90	3.9	40
982	Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. <i>Supportive Care in Cancer</i> , 2011 , 19, 497-504	3.9	43
981	Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. 2011 , 32 Suppl 2, S217-9		1
980	Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. 2011 , 16, 118-24		4
979	Les facteurs de croissance (CSF) biosimilaires : une avancèe ?. 2011 , 13, 201-208		
978	Urgences chez le patient atteint de cancer. 2011 , 13, 455-469		
977	Évaluation gériatrique dans les hémopathies lymphoïdes. 2011 , 13, 589-594		
976	Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. 2011 , 90, 89-94		15
975	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. 2011 , 90, 273-81		12
974	Supportive Therapie in der gynäkologischen Onkologie. 2011 , 44, 717-724		
973	Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis. 2011 , 93, 765-770		1
972	Comorbidity – an important domain in elderly cancer patients' assessment. 2011 , 4, 43-49		2
971	Treatment of myelodysplastic syndromes in elderly patients. 2011 , 28 Suppl 2, 1-9		1
970	First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. 2011 , 28, 304-10		48
969	Les soins de support en oncogériatrie: une aide pour les malades tout au long de la maladie. 2011 , 3, 33-39		2
968	Prévenir et gérer l'urgence fébrile en oncologie. 2011 , 1, 229-231		

967	Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. 2011 , 11, 404	159
966	A phage-targeting strategy for the design of spatiotemporal drug delivery from grafted matrices. 2011 , 4, 7	7
965	Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery. 2011 , 86, 351-2	3
964	Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. 2011 , 117, 1313-20	11
963	Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. 2011 , 117, 1917-27	159
962	Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. 2011 , 29, 177-84	5
961	Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. 2011 , 77, 184-97	21
960	Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. 2011 , 78, 17-23	18
959	Febrile neutropenia: a critical review of the initial management. 2011 , 78, 185-94	38
958	Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. 2011 , 35, 340-5	8
957	Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. 2011 , 35, 358-62	16
956	Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. 2011 , 22, 390-6	18
955	Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. 2011 , 52, 1133-6	5
954	Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 2011 , 103, 1899-901; author reply 1901-3	1
953	Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. 2011 , 11, 1303-13	7
952	Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 2011 , 103, 910-3	26
951	First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. 2011 , 5, 202-12	67
950	Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. 2011 , 17, 225-32	8

949	Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 287-93	2.2	121
948	Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer. <i>Journal of Chemotherapy</i> , 2011 , 23, 36-9	2.3	2
947	Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. 2011 , 103, 979-82		76
946	Diagnosis and management of haematological malignancies in older people. 2011 , 21, 297-311		
945	Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. 2011 , 17, 85-90		3
944	Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. 2011 , 2011, 656013		2
943	Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. <i>Oncologist</i> , 2011 , 16, 197-206	5.7	24
942	Response: Re: Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy. 2011 , 103, 1901-1903		
941	Facteurs de croissance h�matopo�itiques. 2011 , 893-908		1
940	Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. 2011 , 125, 107-14		16
939	Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3877-84	2.2	116
938	Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. 2011 , 34, 241-6		16
937	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. 2011 , 25, 1877-81		86
936	TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. 2011 , 7, 497-506		63
935	Bending the cost curve in cancer care. 2011 , 364, 2060-5		311
934	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. 2011 , 52, 427-31		516
933	Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine. 2011 , 15, E13-23		3
932	Preventing and managing infections in neutropenic stem cell transplantation recipients: evidence-based review. 2011 , 15, 133-9		8

931	CODOX-M/IVAC for non-Hodgkin Lymphomas. 2011 , 46, 91-100		
930	Paclitaxel, Carboplatin, and Bevacizumab. 2011 , 46, 406-414		
929	Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. 2012 , 19, e216-8		8
928	Recombinant Human G-CSF Enhances Recovery and Improves Survival from Severe Radiation-Induced Myelosuppression. 2012 , 365-380		4
927	Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration. 2012 , 4, e2012062		
926	Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. 2012 , 50, 281-9		20
925	Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. <i>Bone Marrow Transplantation</i> , 2012 , 47, 874-6	4.4	20
924	Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences. 2012 , 8, e14s-7s		8
923	Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. 2012 , 35, 267-74		49
922	Twenty years of the colony-stimulating factors. 2012 , 19, 1-2		1
921	Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1064-71	2.2	25
920	The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer. <i>Oncologist</i> , 2012 , 17 Suppl 1, 23-30	5.7	25
919	Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. 2012 , 287, 19574-84		56
918	Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. 2012 , 23, 2166-2172		444
917	A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. 2012 , 23, 1164-1169		35
916	Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. 2012 , 10, CD007913		41
915	[Supportive therapy in medical therapy of head and neck tumors]. 2012 , 91 Suppl 1, S151-75		2
914	Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma. 2012 , 2, 49-58		5

913	Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 806-12	2.2	25
912	Evaluation of infection control advice for patients at risk of chemotherapy-induced neutropenia in 2 pediatric oncology centers: Cape Town, South Africa, and Newcastle-Upon-Tyne, UK. 2012 , 29, 73-84		3
911	[Focus on granulocyte colony-stimulating factor-induced pulmonary toxicity]. 2012 , 99, 211-7		
910	Twenty Years of G-CSF. 2012 ,		6
909	Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. 2012 , 18, 171-9		82
908	Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. 2012 , 107, 814-22		26
907	American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1715-24	2.2	433
906	Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. 2012 , 178, 403-13		48
905	Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. 2012 , 53, 57-63		17
904	A way forward on the medically appropriate use of white cell growth factors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1584-7	2.2	11
903	Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. 2012 , 58, 8-18		38
902	Supportive care in hemato-oncology: a review in light of the latest guidelines. 2012 , 29, 1-9		
901	Present status of adjuvant chemotherapy for elderly breast cancer patients. 2012 , 7, 439-44		3
900	A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. 2012 , 103, 367-82		86
899	Infectious complications in leukemia. 772-793		
898	Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage. 2012 , 3, 860-864		6
897	Cabazitaxel for prostate cancer: patient preparation and ongoing care. 2012 , 21, S13-S17		2
896	Principles of chemotherapy. 2012 , 119 Suppl 2, S151-4		3

895	Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. 2012 , 32, 1070-7		8
894	Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. <i>Supportive Care in Cancer</i> , 2012 , 20, 2017-24	3.9	14
893	Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2012 , 20, 2523-30	3.9	45
892	A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer. 2012 , 30, 309-16		7
891	Antibioprophylaxie et facteurs de croissance mullaire dans la prise en charge du cancer bronchique. 2012 , 4, 530-536		
890	L'ducation thfapeutique d'un patient atteint de toxicit'hmatologique secondaire ^ une chimiothfapie. 2012 , 51, 6-8		
889	The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. 2012 , 39, 573-81		3
888	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). 2012 , 53, 445-50		16
887	Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 2012 , 30, 103-18		9
886	Emergencies in Pediatric Oncology. 2012 ,		1
885	Use of rHuG-CSF for the Treatment of Myeloid Leukemia and in Targeting Leukemia Stem Cells. 2012 , 169-182		
884	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3499-506	2.2	1000
883	Therapeutic strategies in elderly and very elderly patients. 2012 , 25, 91-100		6
882	The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. 2012 , 48, 360-7		15
881	A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). 2012 , 48, 713-20		23
880	Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas. 2012 , 23, 255-60		4
879	Approach to the Patient with Cancer. 2012 , 1164-1177		1
878	Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice. 2012 , 12, 362		10

877	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. 2012 , 16 Suppl 2, S111-7	12
876	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. 2012 , 159, 541-64	89
875	ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs--threshold doses for tissue reactions in a radiation protection context. 2012 , 41, 1-322	709
874	How to manage neutropenia in multiple myeloma. 2012 , 12, 5-11	33
873	Estimation of the incidence of febrile neutropenia in women receiving docetaxel plus cyclophosphamide as adjuvant therapy for early-stage breast cancer: a large community-based retrospective study. 2012 , 9, 158-164	2
872	Biosimilars and their use in hematology and oncology. 2012 , 9, 198-205	0
871	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. 2012 , 83, 341-52	10
870	Haematological support, fatigue and elderly patients. 2012 , 3, 246-255	
869	68-year-old man with neutropenic fever and upper extremity hematoma. 2012 , 87, 1226-9	1
868	Hematopoietic growth factors: personalization of risks and benefits. 2012 , 6, 237-41	10
867	Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis. 2012 , 35, 2013-20	4
866	Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. 2012 , 12, 699-709	6
865	Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. 2012 , CD008238	19
864	Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. 2012 , 30, 497-511	18
863	Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia. 2012 , 25, 209-221	8
862	Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. 2012 , 58, 387-98	25
861	Bacteria and Cancer. 2012 ,	4
860	The critically-ill pediatric hemato-oncology patient: epidemiology, management, and strategy of transfer to the pediatric intensive care unit. 2012 , 2, 14	30

859	Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. 2012 , 7, e42798	11
858	Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. 2012 , 99, 75-80	4
857	[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. 2012 , 99, 875-80	4
856	Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis. 2012 , 19, 332-4	16
855	Infections in Leukemia. 2012 ,	9
854	Gemcitabine, Docetaxel, and Capecitabine (GTX) Regimen for Metastatic Pancreatic Cancer. 2012 , 47, 432-440	
853	Approach to Fever and Suspected Infection in the Compromised Host. 2012 , 1774-1780	
852	Cisplatin, Epirubicin, Levoleucovorin (or Leucovorin), and Fluorouracil (PELF) Regimen for Gastric Cancer. 2012 , 47, 834-840	
851	Skin and soft tissue infections in patients with solid tumours. 2012 , 2012, 804518	10
850	Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. 2012 , 19, e239-43	9
849	Cisplatin, Vinblastine, and Dacarbazine (CVD) Regimen for Melanoma. 2012 , 47, 518-523	
848	Prolonged febrile neutropenia in the pediatric patient with cancer. 2012 , 565-9	1
847	Novel and Targeted Therapies. 2012 , 95-101	
846	Acute radiation syndrome (ARS) - treatment of the reduced host defense. 2012 , 5, 105-15	26
845	Caplri (Xellri) Regimen for Advanced and Metastatic Colorectal or Esophogastric Cancer. 2012 , 47, 98-105	
844	Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer: a systematic review. 2012 , 2,	4
843	Docetaxel, Carboplatin, and Trastuzumab (TCH) for HER2-Positive Breast Cancer. 2012 , 47, 187-192	
842	Chemotherapy. 2012 , 89-94	

841	Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. 2012 , 32, 7-19		11
840	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1534-40	2.2	379
839	Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. 2012 , 149, 1284-97		353
838	Anti-CD20 antibody therapy for B-cell lymphomas. 2012 , 366, 2008-16		228
837	Dynamics of monocyte count: a good predictor for timing of peripheral blood stem cell collection. 2012 , 27, 193-9		4
836	Colony stimulating factors (CSF) biosimilars. Progress?. 2012 , 7 Suppl 1, S17-24		1
835	The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 881-90	3.5	22
834	[Myelopoiesis and bone marrow function in elderly tumor patients]. 2012 , 45, 197-200		2
833	Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. 2012 , 124, 412-8		1
832	Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. <i>Supportive Care in Cancer</i> , 2012 , 20, 1525-32	3.9	38
831	MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. 2012 , 132, 947-53		17
830	Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. 2012 , 109 Suppl 2, 14-9		2
829	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. 2012 , 81, 136-50		13
828	Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. 2012 , 21, 389-93		26
827	Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer. 2012 , 8, 62-70		2
826	The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. 2012 , 36, 548-53		25
825	Building the niche: the role of the S100 proteins in metastatic growth. 2012 , 22, 216-25		100
824	The principles of cancer treatment by chemotherapy. 2012 , 30, 186-190		14

823	Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. 2012 , 125, 625-30		25
822	Treatment of the elderly patient with diffuse large B cell lymphoma. 2012 , 157, 159-70		30
821	Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide?. 2012 , 26, 16-22		12
820	Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 215-20	3-5	13
819	Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. 2012 , 131, 713-21		15
818	Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. <i>Supportive Care in Cancer</i> , 2012 , 20, 647-52	3-9	38
817	Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?. 2013 , 35, 513-9		3
816	Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor. 2013 , 35, 45-50		1
815	The comparison of Filgrastim (Neupogen [®]), biosimilar filgrastim (Leucostim [®]) and Lenograstim (Granocyte [®]) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoietic stem cell transplantation: a single center experience from Turkey. 2013 , 48, 315-20		23
814	Chemotherapy dosing in overweight and obese patients with cancer. 2013 , 10, 451-9		62
813	Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. 2013 , 13, 60		37
812	Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. <i>Supportive Care in Cancer</i> , 2013 , 21, 2861-8	3-9	15
811	Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2013 , 21, 2137-43	3-9	13
810	Side Effects of Medical Cancer Therapy. 2013 ,		2
809	A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. 2013 , 139, 863-72		30
808	Early death in patients diagnosed with non-Hodgkin's lymphoma. 2013 , 92, 345-50		14
807	Febrile neutropenia in hematologic malignancies. 2013 , 8, 370-8		24
806	[Infections in hemato-oncology patients in intensive care. An interdisciplinary challenge]. 2013 , 108, 197-202	o	

805	Neutropenia febbrile e Pronto Soccorso. 2013 , 17, 1-12		
804	Risk factors for refractory febrile neutropenia in urological chemotherapy. 2013 , 19, 211-6		7
803	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. 2013 , 49, 2877-83		25
802	Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost. 2013 , 19, 298-304		10
801	Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 584-91	2.2	127
800	Bone Marrow Toxicity: White Blood Cells. 2013 , 365-380		
799	Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. 2013 , 18, 263-78		8
798	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. 2013 , 14, 525-33		200
797	Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4290-6	2.2	32
796	Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. 2013 , 56, 711-7		105
795	Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. 2013 , 17, 425-33		17
794	Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer. 2013 , 30, 1041-66		7
793	Study design: two long-term observational studies of the biosimilar filgrastim Nivestimã (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. 2013 , 13, 547		6
792	A Revolution in Nanomedicines. 2013 , 107-123		
791	Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2013 , 6, 131-3	2.8	1
790	External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. 2013 , 54, 2426-32		7
789	Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. <i>Supportive Care in Cancer</i> , 2013 , 21, 841-6	3.9	19
788	Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBT) group survey. 2013 , 6, 14-9		20

787	Are aging biomarkers clinically relevant in oncogeriatrics?. 2013 , 85, 257-65	31
786	Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma?. 2013 , 49, 51-5	3
785	Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. 2013 , 4, 48-57	9
784	Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies. 2013 , 4, 310-8	14
783	Mitigating effects of hUCB-MSCs on the hematopoietic syndrome resulting from total body irradiation. 2013 , 41, 346-53.e2	27
782	A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation. 2013 , 13, 42-7	3
781	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. 2013 , 14, 893-900	123
780	Clinico-pathological features of breast carcinoma in elderly Egyptian patients: a comparison with the non-elderly using population-based data. 2013 , 25, 5-11	22
779	Aplasie fébrile du cancer bronchique. 2013 , 5, 37-41	
778	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. 2013 , 49, 482-91	33
777	Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. 2013 , 85, 373-82	21
776	Evaluation of biological rhythms in elderly cancer patients. A complementary translational research within the frame of the trans-hospital pilot program of oncogeriatrics launched at CHC-Liège. 2013 , 61, e33-7	
775	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. 2013 , 14, 38-47	536
774	Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). 2013 , 13, 11	59
773	Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 2013 , 92, 433-42	85
772	Febrile neutropenia: outline of management. 2013 , 80, 138-43	7
771	Colony-stimulating factors for febrile neutropenia during cancer therapy. 2013 , 368, 1131-9	116
770	Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms. 2013 , 1347-1361	

769	Evaluation and Management of Bacterial and Fungal Infections Occurring in Patients with a Hematological Malignancy: A 2011 Update. 2013 , 1165-1191		
768	The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. <i>Supportive Care in Cancer</i> , 2013 , 21, 1793-5	3.9	4
767	Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. <i>European Urology</i> , 2013 , 63, 977-82 ^{10.2}		55
766	Filgrastim improves survival in lethally irradiated nonhuman primates. 2013 , 179, 89-100		108
765	Effect of recombinant Ganoderma lucidum immunoregulatory protein on cyclophosphamide-induced leukopenia in mice. 2013 , 35, 426-33		13
764	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. 2013 , 31, 1300-6		20
763	A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. 2013 , 16, 720-35		56
762	[S3-guideline exocrine pancreatic cancer]. <i>Zeitschrift Fur Gastroenterologie</i> , 2013 , 51, 1395-440	1.6	127
761	[Fever and neutropenia]. 2013 , 102, 1341-8, quiz 1349-50		
760	A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors. 2013 , 19, 328-37		5
759	Neutropenia and G-CSF in lymphoproliferative diseases. 2013 , 18, 131-7		6
758	Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. 2013 , 48, 905-11		0
757	A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: outcomes at 2 years. 2013 , 98, F46-53		20
756	Effets secondaires, complications et s�quelles de la chimioth�apie. 2013 , 125-147		
755	Docetaxel and Cisplatin regimen for non-small-cell lung cancer. 2013 , 48, 550-7		2
754	Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. 2013 , 9, e241-7		30
753	Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. 2013 , 36, 198-205		2
752	Effectiveness of 3-week intervention of Shi Quan Da Bu Tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy. 2013 , 12, 136-44		18

751	The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. 2013 , 24, 2475-2484		122
750	Management of chemotherapy-induced neutropenic fever. 2013 , 41, 96-108		3
749	Immunotherapy for invasive mold disease in severely immunosuppressed patients. 2013 , 57, 94-100		14
748	Neutropenic sepsis: management and complications. 2013 , 13, 185-7		14
747	Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. 2013 , 105, 1078-85		22
746	Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4283-9	2.2	26
745	Pharmacology of aging and cancer: how useful are pharmacokinetic tests?. 2013 , 38, 104-23		
744	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. 2013 , 24, 1038-44		10
743	Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. 2013 , 19, 111-20		10
742	The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. 2013 , 43, 865-73		6
741	Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. 2013 , 173, 559-68		71
740	Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. 2013 , 9, 203-6		23
739	Helical irradiation of the total skin with dose painting to replace total skin electron beam therapy for therapy-refractory cutaneous CD4+ T-cell lymphoma. 2013 , 2013, 717589		14
738	5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. 2013 , 59, 273-9		41
737	Clinical pharmacy services and research for lymphoma patients at a cancer center. 2013 , 19, 24-30		10
736	Comparison of filgrastim and lenograstim in pediatric solid tumors. 2013 , 30, 655-61		5
735	The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo. 2013 , 12, 2241-2247		3
734	Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2013 , 31, 794-810	2.2	309

733	Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. 2013 , 29, 505-15		15
732	Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. <i>Bone Marrow Transplantation</i> , 2013 , 48, 922-5	4-4	22
731	Treatment options for esophageal squamous cell carcinoma. 2013 , 14, 1345-54		56
730	Cabazitaxel: A New Treatment for Metastatic Castration-Resistant Prostate Cancer. 2013 , 7, 66-72		
729	Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center. 2013 , 9, e203-11		14
728	Malignes Melanom S3-Leitlinie âDiagnostik, Therapie und Nachsorge des Melanomsâ 2013 , 11, 1-126		3
727	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". 2013 , 11 Suppl 6, 1-116, 1-126		79
726	Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model. 2013 , 121, 996-1007		9
725	Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. 2013 , 8, 96-101		46
724	Colony-Stimulating Factors for Prevention and Treatment of Neutropenia and Infectious Diseases. 2013 , 399-417		1
723	Neutrophie fbrile et urgences. 2013 , 8, 1-12		1
722	Canadian consensus guidelines for the management of testicular germ cell cancer. 2010 , 4, e19-38		99
721	Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. 2013 , 20, e171-9		16
720	Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. 2013 , 48, 87-98		10
719	Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. 2013 , 5, 357-65		21
718	Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. 2013 , 9, 457-62		11
717	Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer. 2013 , 48, 274-9		1
716	Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study. 2014 , 9, e96413		9

715	Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis. 2014 , 9, e107273	7
714	Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. 2014 , 9, e110469	20
713	A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen. 2014 , 2014, 1-7	1
712	Preclinical profile of cabazitaxel. 2014 , 8, 1851-67	45
711	Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. 2014 , 4, 280-9	36
710	Presentation and management of docetaxel-related adverse effects in patients with breast cancer. 2014 , 6, 253-9	103
709	Prophylactic low-dose G-CSF in patients with breast cancer experiencing grade 4 neutropenia during their previous (neo-) adjuvant (F)EC-chemotherapy cycle: Results of a pilot study. 2014 , 4,	
708	The use of granulocyte colony-stimulating factors in a Canadian outpatient setting. 2014 , 21, e229-40	3
707	Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. 2014 , 17, 356-62	6
706	Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. 2014 , 18, 419-24	
705	Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 2014 , 29, 1493-500	13
704	Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan. 2014 , 25, 124-9	3
703	Granulocyte Colony-stimulating Factors Used in Clinical Practice: PoloNord Registry-Based Cohort Italian Study. 2014 , 100, 491-498	10
702	Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients. 2014 , 21, e52-61	8
701	Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. 2014 , 6, 87-96	25
700	. 2014 ,	2
699	Comparison of Therapeutic G-CSF Cycles and Prophylactic G-CSF Cycles in Patients Receiving Paclitaxel and Carboplatin Combination Chemotherapy for Ovarian Cancer: A Retrospective Study Report. 2014 , 9, 86-9	3
698	Cancer in the Elderly: Biology, Prevention, and Treatment. 2014 , 904-913.e2	

697 PharmaNews / PharmaTicker. **2014**, 9, 143-144

696 Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. **2014**, 13, 1165-73 21

695 Anthracyclines. **2014**, 683-694 4

694 The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action. **2014**, 10, 61 26

693 Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren. **2014**, 17, 38-47

692 Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. **2014**, 30, 2523-33 14

691 Modelling chemotherapy effects on granulopoiesis. **2014**, 8, 138 12

690 A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. **2014**, 148, 107-16 27

689 Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. **2014**, 28, 1573-85 84

688 Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. **2014**, 17, 32-42 18

687 Capecitabine and Gemcitabine (CapGem, CG, GemCap) for Advanced Pancreatic and Biliary Tract Cancer. **2014**, 49, 127-33 1

686 Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer. **2014**, 49, 425-31 4

685 Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and Non-Small-Cell Lung Cancer. **2014**, 49, 603-11

684 Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer. **2014**, 44, 1040-4 5

683 Setting the bar: developing quality measures and education programs to define evidence-based, patient-centered, high-quality care. **2014**, 18 Suppl, 7-11 16

682 Paclitaxel and trastuzumab for breast cancer. **2014**, 49, 338-44 1

681 Paclitaxel, Carboplatin, and trastuzumab. **2014**, 49, 913-9 1

680 Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. **2014**, 9, 239-45 29

679	Gemcitabine and Vinorelbine (GemVin) Regimen. 2014 , 49, 508-16		1
678	G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and G-CSF use. 2014 , 3, 1477-84		38
677	Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. 2014 , 55, 526-32		36
676	Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. 2014 , 3, 434-44		60
675	Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. 2014 , 92, 268-78		10
674	Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. 2014 , 34, 633-42		2
673	Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. 2014 , 120, 43-51		14
672	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. 2014 , 93, 207-13		11
671	G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. 2014 , 25, 355-67		185
670	Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. 2014 , 44, 416-21		10
669	Neutropenic fever and sepsis: evaluation and management. 2014 , 161, 181-202		12
668	Growth factor use in medication-induced hematologic toxicity. 2014 , 27, 453-60		7
667	Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer. 2014 , 25, 511-8		8
666	A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. 2014 , 25, 505-11		16
665	Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 1005-13	3.5	11
664	Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. <i>Supportive Care in Cancer</i> , 2014 , 22, 3227-34	3.9	9
663	Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2014 , 22, 3219-26	3.9	11
662	Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. <i>Supportive Care in Cancer</i> , 2014 , 22, 3275-85	3.9	18

661	Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. 2014 , 25, 964-9		18
660	Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 1241-50	3.5	34
659	Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. 2014 , 37, 603-10		11
658	Feasibility re-evaluation of 75 mg/m ² docetaxel in Japanese patients with previously treated non-small cell lung cancer. 2014 , 44, 338-45		3
657	Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. 2014 , 55, 56-62		2
656	Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009. 2014 , 31, 242		3
655	Pegfilgrastim-induced pain in patients with lymphoma. 2014 , 41, 212-4		2
654	Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: a retrospective analysis. 2014 , 10, e54-62		2
653	Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010). 2014 , 12, 266-76		12
652	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). 2014 , 84, 67-72		44
651	Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. 2014 , 133, 446-53		7
650	Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. 2014 , 133, 439-45		20
649	Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. 2014 , 50, 320-31		171
648	A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. 2014 , 31, 797		17
647	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. 2014 , 50, 1090-9		68
646	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. 2014 , 89, 243-8		12
645	Severe neutropenia and relative dose intensity among patients. <i>Supportive Care in Cancer</i> , 2014 , 22, 1833-41		4
644	Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP. 2014 , 19, 178-85		2

643	Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer. 2014 , 16, 814-22		7
642	Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. <i>Supportive Care in Cancer</i> , 2014 , 22, 667-77	3.9	23
641	Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. 2014 , 35, 3641-9		11
640	Neutropenic Fever. 2014 , 3, e218-e234		
639	New G-CSF agonists for neutropenia therapy. 2014 , 23, 21-35		19
638	Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. 2014 , 90, 190-9		147
637	Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014 , 49, 219-22	4.4	6
636	Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. 2014 , 14, 241-7		16
635	Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. 2014 , 31, 683-95		8
634	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. <i>Oncologist</i> , 2014 , 19, 693-701	5.7	48
633	Delivering Chemotherapy on Intensive Care. 2014 , 196-203		
632	Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). 2014 , 25, 1709-1718		27
631	Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer. 2014 , 36, 1287-94		3
630	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. 2014 , 15, 1019-26		215
629	Infectious Complications in the Immunosuppressed Patient. 2014 , 123-134		
628	Supportive care considerations for older adults with cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2627-34		49
627	Preventing infections during cancer treatment: development of an interactive patient education website. 2014 , 18, 426-31		7
626	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. 2014 , 38, 1269-77		10

625	Adjuvant chemotherapy in older women with breast cancer: who and what?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1996-2000	2.2	20
624	Supportive Therapie und Schmerzbehandlung. 2014 , 47, 496-500		
623	A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma. 2014 , 93, 1637-44		10
622	Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. <i>Supportive Care in Cancer</i> , 2014 , 22, 1619-28	3.9	12
621	Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres. <i>Supportive Care in Cancer</i> , 2014 , 22, 2033-7	3.9	2
620	Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. <i>Supportive Care in Cancer</i> , 2014 , 22, 2167-75	3.9	15
619	Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. <i>Supportive Care in Cancer</i> , 2014 , 22, 2831-7	3.9	17
618	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. 2014 , 14, 201		18
617	Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. 2014 , 14, 189		32
616	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2014 , 49, 950-4	4.4	5
615	Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2067-73	2.2	55
614	Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. 2014 , 45, 460-5		15
613	Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients. 2014 , 23, 676-82		7
612	Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. 2014 , 17, 739-43		2
611	Efficacy and safety of balgrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. 2014 , 14, 101-8		20
610	Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. 2014 , 71, 34-57		62
609	Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. 2014 , 91, 248-56		21
608	Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. 2014 , 17, 380-9		22

607	Febrile neutropenia risk assessment tool: improving clinical outcomes for oncology patients. 2014 , 18, 167-74	6
606	Update on adjuvant chemotherapy for early breast cancer. 2014 , 8, 125-33	27
605	Medical problems and radiotherapy emergencies. 2014 , 130-147	
604	Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. 2014 , 3, 108	1
603	A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. 2014 , 23, 13-20	1
602	Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. 2015 , 26, 1054-60	21
601	Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?. 2015 , 4, 1153-60	16
600	Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). 2015 , 116, 880-7	30
599	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. 2015 , 54, 2969-73	9
598	Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use. 2015 , 13, 979-86	13
597	Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. 2015 , 13, e1-7	28
596	Practical issues in the use of systemic anti-cancer therapy drugs. 1-12	
595	Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. 2015 , 49, 173-80	9
594	Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach. 2015 , 22, 3-6	7
593	Palliative Care in Older Patients With Cancer. 2015 , 22, 480-8	12
592	Tumoren des oberen Gastrointestinaltraktes. <i>Best Practice Onkologie</i> , 2015 , 10, 19-28	0
591	[Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. 2015 , 86, 1014-22	1
590	Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. 2015 , 29, 1128-32	3

589	Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey. 2015 , 15, 651	1
588	Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?. 2015 , 35, 167-71	4
587	Acute oncology 1: oncological emergencies. 96-111	
586	Haematological manifestations of human immune deficiency virus infection. 2015 , 171, 695-709	29
585	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. 2015 , 55, 2351-7	3
584	Diffuse Reactive Angioendotheliomatosis Secondary to the Administration of Trabectedin and Pegfilgrastim. 2015 , 37, 581-4	5
583	Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. 2015 , 9, 5785-91	24
582	Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme. 2015 , 50, 672-7	1
581	Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases. 2015 , 6, 1322	28
580	Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study. 2015 , 19, 214-9	6
579	Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. 2015 , 10, e0123978	18
578	Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. 2015 , 3, 725-729	3
577	Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors. 2015 , 19, 37-47	15
576	Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma. 2015 , 50, 025-030	
575	Hematopoietic Growth Factors and Cytokines. 2015 , 789-808.e4	1
574	How I treat Waldenström macroglobulinemia. 2015 , 126, 721-32	105
573	Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. 2015 , 20, 605-12	22
572	Management of Acute Radiation Side Effects. 2015 , 203-221	1

571	The Diagnostic Approach to the Febrile Neutropenic Patient: Clinical Considerations. 2015 , 91-111	1
570	Aldoxorubicin for the treatment of advanced soft tissue sarcoma. 2015 , 3, 457-466	
569	Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren. 2015 , 19, 24-33	
568	Cutting the brakes on hematopoietic regeneration by blocking TGF β to limit chemotherapy-induced myelosuppression. 2015 , 2, e978703	5
567	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy. 2015 , 25, 1331-6	11
566	Clinical perspectives: practical insights from clinical experience with cabazitaxel in Australia. 2015 , 11, 199-207	5
565	Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. 2015 , 183, 643-55	71
564	Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. 2015 , 165, 387-94	5
563	Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. 2015 , 10, 1221-8	17
562	Principles of chemotherapy. 2015 , 131 Suppl 2, S146-9	13
561	The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. 2015 , 4, 396	10
560	Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design. 2015 , 4, 37-50	1
559	In-Situ Gelling Polymers. 2015 ,	1
558	Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. 2015 , 6, 141-52	47
557	Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. 2015 , 169, 293-6	7
556	Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2015 , 50, 523-30	4.4 24
555	Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. 2015 , 8, 15-24	14
554	Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. <i>Supportive Care in Cancer</i> , 2015 , 23, 643-9	3.9 3

553	Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool. 2015 , 51, 427-35		13
552	Supportive Care in Pediatric Oncology. 2015 ,		1
551	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. 2015 , 372, 724-34		1242
550	Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. <i>Supportive Care in Cancer</i> , 2015 , 23, 1137-43	3.9	56
549	The principles of cancer treatment by chemotherapy. 2015 , 33, 131-135		10
548	First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 929-39	3.5	3
547	A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. <i>Supportive Care in Cancer</i> , 2015 , 23, 1759-67	3.9	9
546	Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. 2015 , 33, 594-602		5
545	Pharmacokinetic study of doxorubicin in patients with solid tumors. 2015 , 33, 341-8		40
544	Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment. 2015 , 32, 654-64		7
543	Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. 2015 , 11, 47-54		48
542	Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas. 2015 , 50, 194-8		
541	Peptidic Hydrogels. 2015 , 127-150		
540	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3199-212	2.2	488
539	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. 2015 , 16, 816-29		213
538	White blood cell growth factor use in an outpatient oncology clinic: Lessons and opportunities learned. 2015 , 21, 213-9		1
537	Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma. 2015 , 50, 25-30		
536	A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). 2015 , 89, 146-53		12

535	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. 2015 , 90, 65-70		36
534	A Case of Granulocyte-Colony Stimulating Factor-Producing Spindle Cell Carcinoma of the Breast. 2015 , 15, e213-7		7
533	Factors predicting severe infections during chemotherapy in head and neck cancer patients. 2015 , 135, 1086-91		4
532	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. 2015 , 16, 704-15		189
531	Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1199-206	3.5	28
530	Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2015 , 23, 2891-8	3.9	18
529	Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma. 2015 , 12, 209-218		1
528	The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. 2015 , 26, 1452-8		18
527	Effect of Granulocyte Colony-Stimulating Factor-Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan. 2015 , 21, 1632-40		10
526	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. 2015 , 385, 1863-72		131
525	Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2015 , 23, 2863-72	3.9	43
524	Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. 2015 , 150, 169-80		9
523	Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. 2015 , 37, 842-57		41
522	The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer. 2015 , 16, 9		2
521	Trabectedin: Supportive care strategies and safety profile. 2015 , 94, 279-90		12
520	Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns. 2015 , 38, 146-52		15
519	The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. <i>Supportive Care in Cancer</i> , 2015 , 23, 3131-40	3.9	72
518	An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. 2015 , 32, 147		11

517	Bersicht âOnkopti - Protokolle f die Chemo- und Supportivtherapie im Internet. 2015 , 36, 81-84		2
516	Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 925-32	3.5	37
515	Delayed hypersensitivity reaction related to the use of pegfilgrastim. 2015 , 21, 474-7		8
514	Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. 2015 , 56, 368-76		
513	G-CSF and GM-CSF in Neutropenia. 2015 , 195, 1341-9		187
512	Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. 2015 , 154, 133-43		20
511	Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. 2015 , 154, 89-97		19
510	Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. 2015 , 4, 316		13
509	The signs, symptoms and help-seeking experiences of neutropenic sepsis patients before they reach hospital: a qualitative study. <i>Supportive Care in Cancer</i> , 2015 , 23, 2687-94	3.9	12
508	The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. 2015 , 153, 591-7		16
507	Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer. 2015 , 14, e21-31		3
506	[How to identify frailty in older patients with cancer? Available tools]. 2015 , 19, 382-5		2
505	Radiation therapy and neutropenia. 2015 , 39, 292-6		6
504	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. 2015 , 33, 942-53		20
503	Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2015 , 23, 2045-51	3.9	22
502	Infections in Hematology. 2015 ,		5
501	Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. <i>Supportive Care in Cancer</i> , 2015 , 23, 301-2	3.9	11
500	Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. <i>Supportive Care in Cancer</i> , 2015 , 23, 547-59	3.9	11

499	Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report. 2015 , 21, 301-4		18
498	Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. <i>Supportive Care in Cancer</i> , 2015 , 23, 525-45	3.9	47
497	The lung cancer patient, the pneumologist and palliative care: a developing alliance. 2015 , 45, 211-26		10
496	Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. 2015 , 56, 694-702		5
495	Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. 2015 , 15, 145-50		22
494	Antifungal Therapy. 2016 ,		3
493	Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. 2016 , 4, 591-596		2
492	Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. 2016 , 9, 506-515		
491	Carboplatin and Liposomal Doxorubicin for Ovarian Cancer. 2016 , 51, 442-9		4
490	Biosimilars in the management of neutropenia: focus on filgrastim. 2016 , 10, 17-22		7
489	Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. 2016 , 7, 317		24
488	Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. 2016 , 19, 76-82		13
487	Informatics Support Across the Cancer Continuum. 2016 , 145-157		
486	Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. 2016 , 5, 300-306		7
485	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. 2016 , 11, e0157751		14
484	Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. 2016 , 11, e0148901		4
483	A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients. 2016 , 71, 586-592		8
482	Neutropenia in Asian patients with solid tumours receiving chemotherapy: A retrospective case-control study. 2016 , 6,		1

481	Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy. 2016 , 38, 191-6		5
480	Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?. 2016 , 27, 239-44		0
479	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. 2016 , 63, e1-e60		1274
478	Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3213-20	2.2	13
477	Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. 2016 , 12, 1359-67		29
476	Administration of G-CSF from day +6 post-allogeneic hematopoietic stem cell transplantation in children and adolescents accelerates neutrophil engraftment but does not appear to have an impact on cost savings. 2016 , 20, 432-7		2
475	???????????? G-CSF ??????????. 2016 , 119, 1097-1104		
474	Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. <i>Scientific Reports</i> , 2016 , 6, 18999	4.9	15
473	High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients. 2016 , 16, 89-97		7
472	A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. <i>Oncologist</i> , 2016 , 21, 7-15	5.7	13
471	Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer. 2016 , 5, 714-716		5
470	Adjuvant treatment for older women with invasive breast cancer. 2016 , 12, 129-45; quiz 145-6		9
469	At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study. <i>Bone Marrow Transplantation</i> , 2016 , 51, 593-5	4.4	5
468	Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents. <i>Oncologist</i> , 2016 , 21, 301-7	5.7	17
467	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1764-71	2.2	102
466	Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. 2016 , 27, 695-707		4
465	A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC). 2016 , 17, 119-27		17
464	A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. <i>Oncologist</i> , 2016 , 21, 789-94	5.7	32

463	Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor Use for Patients With Non-Small-Cell Lung Cancer Who Receive Chemotherapy: An ASCO Quality Training Program Project of the Cleveland Clinic Taussig Cancer Institute. 2016 , 12, e101-7		5
462	Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. 2016 , 65, 334-43		53
461	Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 847-53	3.5	19
460	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. <i>Supportive Care in Cancer</i> , 2016 , 24, 4913-4920	3.9	7
459	Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. <i>Supportive Care in Cancer</i> , 2016 , 24, 4835-4837	3.9	11
458	Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. 2016 , 4, 47-50		3
457	Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. 2016 , 16, 503-510.e3		6
456	Bacterial Infections. 2016 , 1038-1062		
455	R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. 2016 , 95, 1705-14		21
454	Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma. 2016 , 12, 1448-1454		2
453	PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. 2016 , 5, 676-83		37
452	A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. 2016 , 174, 563-70		26
451	Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients. 2016 , 48, 1927-33		4
450	Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. 2016 , 273, 329-43		102
449	Total Body Irradiation. 2016 , 341-357.e7		1
448	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3872-3879	2.2	16
447	To wake up cancer stem cells, or to let them sleep, that is the question. 2016 , 107, 875-81		62
446	What do oncologists need to know about biosimilar products?. 2016 , 35, 91		9

445	Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. 2016 , 27, v111-v118		290
444	Antibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation. 2016 ,		
443	Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study. 2016 , 33, 1983-2000		5
442	Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. 2016 , 21, 1085-1090		17
441	Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. 2016 , 18, 1192-1202		56
440	Blood Transfusions for Hospitalized Patients with Cancer. 2016 , 5, 356-367		
439	A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer. 2016 , 5, 164		13
438	Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study. 2016 , 46, 692-5		3
437	Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. 2016 , 2, CD009310		3
436	Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. 2016 , 22, 702-16		38
435	Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. <i>Supportive Care in Cancer</i> , 2016 , 24, 2677-84	3.9	5
434	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. 2016 , 34, 66-74		12
433	Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. <i>Supportive Care in Cancer</i> , 2016 , 24, 3085-93	3.9	14
432	Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. <i>Supportive Care in Cancer</i> , 2016 , 24, 1563-9	3.9	14
431	Cytotoxic chemotherapy: clinical aspects. 2016 , 44, 25-29		8
430	Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. <i>Supportive Care in Cancer</i> , 2016 , 24, 2481-90	3.9	11
429	HIV-associated Hematological Malignancies. 2016 ,		4
428	Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy. 2016 , 26, 95-103		8

427	Fever of unknown origin in cancer patients. 2016 , 101, 125-30		13
426	Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US. 2016 , 19, 537-47		6
425	Sustained release of active chemotherapeutics from injectable-solid β -hairpin peptide hydrogel. 2016 , 4, 839-48		49
424	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1500-9	2.2	65
423	Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. 2016 , 128, 238-47		9
422	Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016 , 24, 2693-906	3.9	5
421	Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. <i>Supportive Care in Cancer</i> , 2016 , 24, 3185-9	3.9	1
420	Costo- Efectividad Del Uso Profilático Del Factor Estimulante De Colonias De Granulocitos En Adultos Con Leucemia Linfoblástica Aguda en Colombia. 2016 , 11, 9-16		0
419	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2016 , 387, 1163-77		1115
418	Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. 2016 , 27, 608-18		28
417	Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. 2016 , 89, 83-9		10
416	Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study. 2016 , 57, 1657-64		3
415	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. 2016 , 22, 2359-67		22
414	Chemotherapy Basics for Hospitalists. 2016 , 5, 85-100		
413	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. 2016 , 57, 766-82		56
412	Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma. 2016 , 30, 1187-90		7
411	Zarzio [®] , biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. <i>Supportive Care in Cancer</i> , 2016 , 24, 1991-1998	3.9	17
410	PEGylation in anti-cancer therapy: An overview. 2016 , 11, 337-348		220

409	Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016 , 24, 1285-94	3.9	12
408	Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study. <i>Supportive Care in Cancer</i> , 2016 , 24, 395-400 ⁹	3.9	10
407	Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. <i>Supportive Care in Cancer</i> , 2016 , 24, 267-273	3.9	15
406	Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. 2016 , 57, 283-290		7
405	Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. <i>Supportive Care in Cancer</i> , 2016 , 24, 723-730	3.9	12
404	Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany. <i>Supportive Care in Cancer</i> , 2016 , 24, 367-376	3.9	19
403	Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients. 2016 , 22, 423-9		15
402	Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice. 2017 , 23, 33-42		2
401	Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy. 2017 , 11, 453-458		5
400	Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare-based Study. 2017 , 40, 66-74		5
399	Fertility Risk with Cancer Therapy. 2017 , 1-15		
398	Reply to Barroso-Sousa R et'al. 2017 , 34, 131		
397	Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. 2017 , 15, e429-e435		6
396	Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. 2017 , 17, 39-52		2
395	Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study. 2017 , 33, 931-936		3
394	Prophylactic Measures During Induction for Acute Myeloid Leukemia. 2017 , 19, 18		11
393	Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management. 2017 , 51, 797-803		12
392	Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. <i>Supportive Care in Cancer</i> , 2017 , 25, 2787-2795	3.9	20

391	The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. 2017 , 28, 1260-1267		70
390	Evaluation of short-term and long-term efficacy of surgical and non-surgical treatment in patients with early-stage small cell lung cancer: A comparative study. 2017 , 19, 249-256		7
389	Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. <i>Supportive Care in Cancer</i> , 2017 , 25, 3123-3132	3.9	10
388	The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1229-1237	3.5	11
387	Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan. <i>Supportive Care in Cancer</i> , 2017 , 25, 3313-3320	3.9	8
386	Reprint of: Heme oxygenase 1 affects granulopoiesis in mice through control of myelocyte proliferation. 2017 , 222, 846-857		
385	Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. 2017 , 7, e564		30
384	Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety. 2017 , 22, 880-886		3
383	Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion. 2017 , 51, 840-847		8
382	Impact of Abbreviated Filgrastim Schedule on Survival and Hematopoietic Recovery after Irradiation in Four Mouse Strains with Different Radiosensitivity. 2017 , 187, 659-671		17
381	Acute Side Effects of Radiation Therapy. 2017 ,		3
380	Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. 2017 , 99, 112-118		11
379	Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. 2017 , 13, 372-378		12
378	Gastrointestinal emergencies in critically ill cancer patients. 2017 , 40, 69-75		11
377	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. 2017 , 18, 50-59		28
376	The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin's and non-Hodgkin's lymphomas: A scoping review. 2017 , 26, 63-82		16
375	Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. 2017 , 92, 101-108		22
374	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). 2017 , 58, 1814-1822		9

373	Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. 2017 , 52, 341-347		1
372	Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. 2017 , 33, 2107-2113		15
371	Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. 2017 , 33, 2115-2120		8
370	Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges. 2017 , 66, 1509-1527		13
369	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. 2017 , 390, 2266-2277		121
368	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥80 years. 2017 , 92, E567-E574		5
367	JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). 2017 , 106, 310-325		10
366	Oncologic Emergencies. 2017 , 393-408		
365	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. 2017 , 3, 10		70
364	[Choosing wisely recommendations in hematology and oncology]. 2017 , 58, 545-549		0
363	Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas. 2017 , 39, 1161-1170		2
362	Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice. 2017 , 35, 918-920		
361	Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. <i>Supportive Care in Cancer</i> , 2017 , 25, 439-447	3.9	29
360	Heme oxygenase 1 affects granulopoiesis in mice through control of myelocyte proliferation. 2017 , 222, 506-517		7
359	Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. <i>Supportive Care in Cancer</i> , 2017 , 25, 839-845	3.9	15
358	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 2017 , 23, 1167-1176		50
357	Infections in the Cancer Patient. 2017 , 723-738.e3		0
356	Avoidant conversations about death by clinicians cause delays in reporting of neutropenic sepsis: Grounded theory study. 2017 , 26, 1505-1512		1

355	Immunotherapy for Fungal Infections. 2017 ,		2
354	Incidence of chemotherapy-induced neutropenia in HIV-infected and uninfected patients with breast cancer receiving neoadjuvant chemotherapy. 2017 , 107, 595-601		9
353	Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. 2017 , 6, 27		3
352	Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers. 2017 , 06,		
351	The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. 2017 , 63, 1061-1064		0
350	Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan. 2017 , 8, 5-12		6
349	Improving the Management of Patients With Low-Risk Neutropenic Fever at the Cleveland Clinic Taussig Cancer Institute. 2017 , 13, e259-e265		6
348	Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. 2017 , 13, e552-e561		71
347	Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process. 2017 , 13, e273-e282		16
346	Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials. 2017 , 8, 57365-57378		11
345	Principles of cancer treatment by chemotherapy. 2018 , 36, 134-138		37
344	Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis. 2018 , 23, 581-589		4
343	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. 2018 , 151, 39.e1-39.e17		4
342	Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients. 2018 , 104, 742-748		7
341	Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2018 , 26, 2323-2331	3.9	6
340	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. 2018 , 14, 21-25		2
339	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. <i>Expert Review of Hematology</i> , 2018 , 11, 155-168	2.8	1
338	Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. 2018 , 168, 389-399		12

337	Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. <i>Oncologist</i> , 2018 , 23, 403-409	5-7	7
336	Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. 2018 , 48, 410-416		3
335	Medication overuse in oncology: current trends and future implications for patients and society. 2018 , 19, e200-e208		15
334	Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. 2018 , 121, 203-208		8
333	Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis. 2018 , 34, 1351-1360		6
332	Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. 2018 , 19, e163-e169		18
331	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. 2017 ,		5
330	Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer. <i>Supportive Care in Cancer</i> , 2018 , 26, 33-40	3-9	4
329	Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2018 , 26, 539-548	3-9	6
328	Fever and Granulocytopenia. 2018 , 578-586.e4		
327	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. 2018 , 84, 490-500		9
326	A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells. 2018 , 119, 6408-6417		9
325	MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis. 2018 , 100, 241-246		4
324	Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders. 2018 , 24, 609-616		3
323	Supportive care. 2018 ,		
322	Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. 2018 , 10,		44
321	Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients. 2018 , 25, e423-e429		4
320	Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. 2019 , 10, 21-27		2

319	Immunomodulation as a Therapy for Infection: Current Status and Future Perspectives. 2018 , 4,	14
318	Management of unfit elderly patients with chronic lymphocytic leukemia. 2018 , 58, 7-13	5
317	Infections and Cancer. 2018 , 337-348	
316	Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. 2018 , 10, 493-500	6
315	Home administration of filgrastim (Nivestim®) in primary prophylaxis of chemotherapy-induced febrile neutropenia. 2018 , 12, 2179-2186	2
314	Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy. 2018 , 36, 424-430	1
313	Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. 2018 , 16, 437-444.e6	3
312	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). 2018 , 2, 1705-1718	9
311	Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation. 2018 , 25, 671-680	4
310	Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. 2018 , 38, 4381-4386	
309	Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. 2018 , 34, 1705-1711	7
308	Management of Advanced Prostate Cancer. 2018 ,	1
307	Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms. 2018 , 1247-1262	
306	Is There a Role for Hematopoietic Growth Factors During Sepsis?. 2018 , 9, 1015	16
305	A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation. 2018 , 44, 63	1
304	Systemic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. 2018 , 167-173	
303	Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy. 2018 , 24, 976-984	13
302	The prognostic impact of abdominal surgery in cancer patients with neutropenic enterocolitis: a systematic review and meta-analysis, on behalf the Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GRRR-OH). 2018 , 8, 47	11

301	Immunomodulation as Therapy for Fungal Infection: Are We Closer?. 2018 , 9, 1612	28
300	Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONY Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L). 2018 , 19, e865-e869	2
299	Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution. <i>Supportive Care in Cancer</i> , 2018 , 26, 4097-4103 ³⁻⁹	4
298	Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 165-170	3-5 4
297	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. 2018 , 151, 39.e1-39.e17	1
296	Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. 2019 , 25, 1357-1365	5
295	Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant. 2019 , 35, 66-71	1
294	Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. 2019 , 19, 792	9
293	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. 2019 , 14, 207-218	6
292	A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. 2019 , 14, e0224299	4
291	Oncologic Emergencies: The Fever With Too Few Neutrophils. 2019 , 57, 689-700	2
290	Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. <i>Scientific Reports</i> , 2019 , 9, 15374 ⁹	10
289	. 2019 ,	1
288	Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy. 2019 , 204, 107403	2
287	[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. 2019 , 23, 273-280	7
286	Adaptive Immunotherapy for Opportunistic Infections. 2019 , 1019-1030	
285	A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma. 2019 , 8, 2994-3003	7
284	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. 2019 , 35, 1761-1767	1

283 Fertility Risk with Cancer Therapy. **2019**, 3-14

282 A Novel Methanol-Free Platform for Extracellular Expression of rhGM-CSF in *Pichia pastoris*. **2019**, 61, 521-527 2

281 Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study. *Supportive Care in Cancer*, **2019**, 27, 4283-4292 3.9 3

280 Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. **2019**, 20, e218-e223 23

279 Emerging therapies in Parkinson disease - repurposed drugs and new approaches. **2019**, 15, 204-223 100

278 Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer. **2019**, 10, 1005-1008 4

277 Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study. **2019**, 28, e13034 2

276 Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management. **2019**, 138, 1-5 4

275 A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. **2019**, 120, 475-480 58

274 Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. **2019**, 19, 122 2

273 Supportive care. **2019**,

272 The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy. **2019**, 59, 1140-1150

271 Articles Title ch_6. **2019**,

270 SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. **2019**, e28087 7

269 A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy. **2019**, 41, 525-531 2

268 Granulocyte-Colony-Stimulating Factor Effectively Shortens Recovery Duration in Anti-Thyroid-Drug-Induced Agranulocytosis: A Systematic Review and Meta-Analysis. **2019**, 10, 789 1

267 Comprehensive review of oncological emergencies seen in clinical practice. **2019**, 35, 69-81

266 A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer. **2019**, 19, 1-9 6

265	Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. 2019 , 35, 725-730		3
264	Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. 2019 , 35, 1073-1080		9
263	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. 2019 , 19, 149-156		2
262	SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). 2019 , 21, 75-86		8
261	Adverse drug reactions of anticancer drugs derived from natural sources. 2019 , 123, 522-535		41
260	Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. <i>Supportive Care in Cancer</i> , 2019 , 27, 3019-3025	3.9	2
259	Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. 2019 , 125, 1143-1154		9
258	Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population. 2019 , 35, 229-240		2
257	Oncologic Emergencies-The Old, the New, and the Deadly. 2020 , 35, 3-13		10
256	Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim. 2020 , 33, 779-783		2
255	Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System. 2020 , 26, 923-928		3
254	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. 2020 , 21, 105-120		35
253	Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. 2020 , 36, 483-495		6
252	The effect of Absolute Neutrophil Count (ANC) on early surgical site infection in Implanted Central Venous Catheter (ICVC). 2020 , 55, 1344-1346		2
251	Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer. 2020 , 38, 424-430		0
250	Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21. 2020 , 61, 2998-3001 ⁰		0
249	Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. 2020 , 1-17		13
248	Using electronic health record data to identify comparator populations for comparative effectiveness research. 2020 , 23, 1618-1622		3

247	Involvement of oral bacteria and oral immunity as risk factors for chemotherapy-induced fever with neutropenia in patients with hematological cancer. 2020 , 112, 851-859	
246	Saikosaponin d contributed to cancer chemotherapy induced neutropenia therapy by promoting neutrophil differentiation via activation CBL-dependent ERK pathway. 2020 , 160, 105149	1
245	Neutropenic Enterocolitis in the Treatment of Solid Tumors: A Case Report and Review of the Literature. 2020 , 13, 442-448	2
244	Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach. 2020 , 86, 2473-2485	2
243	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. 2020 , 26, 4468-4477	4
242	Use of granulocyte-colony stimulating factors in older patients: a review of recently published data. 2020 , 32, 258-261	
241	Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India. 2020 , 84, 102445	3
240	An Open-Label, Prospective Study Evaluating the Clinical and Immunological Effects of Higher Dose Granulocyte Colony-Stimulating Factor in ALS. 2020 , 21, 127-134	2
239	Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?. 2020 , 93, 20190147	6
238	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. 2020 , 20, 358	2
237	Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. 2020 , 20, 439-447	1
236	Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations. 2021 , 45, 100690	11
235	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. 2021 , 51, 199-204	
234	Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. 2021 , 148, 375-384	4
233	Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. 2021 , 62, 791-800	0
232	Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. 2021 , 157, 103193	2
231	Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects. 2021 , 41, 29-42	1
230	Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. <i>Supportive Care in Cancer</i> , 2021 , 29, 2179-2186	3.9 7

229	A Novel PCR Method for Detecting ACE Gene Insertion/Deletion Polymorphisms and its Clinical Application. 2021 , 23, 2		2
228	Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimtia [®] BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy. <i>Journal of Modern Oncology</i> , 2020 , 22, 77-84	0.3	1
227	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. 2021 , 22, 857-865		0
226	Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease. 2021 , 60, 103059		0
225	Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. 2021 , 21, 341		2
224	Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2020 edition). 2021 , 5, 4-11		
223	Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. <i>Cancers</i> , 2021 , 13,	6.6	1
222	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021 , 26, 483-491	5.7	2
221	Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients. 2021 , 17 Suppl 3, 39-47		2
220	Principles of cancer treatment by chemotherapy. 2021 , 39, 215-220		3
219	Impact of a G-CSF Policy to Reduce Low-Value Care on Guideline Adherence and Mortality. 2021 , 17, e1830-e1836		3
218	Neutropenia in breast cancer patients receiving Paclitaxel as chemotherapy: a study in a tertiary care centre in Northeast India. 2021 , 7, 9		
217	Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. 2021 , 33, e13005		1
216	Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. 2021 , 37, 100853		
215	Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. 2021 , 17, e1235-e1245		4
214	Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. 2021 , 10,		1
213	Sepsis Inflammation Impairs the Generation of Functional Dendritic Cells by Targeting Their Progenitors. 2021 , 12, 732612		1
212	APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin. 2021 , 240, 110322		0

211	Aging and Cancer: What Oncologists Need to Know. 2009 , 1-15	1
210	Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. 2011 , 157, 167-78	2
209	The hematopoietic growth factors in acute leukemia: U.S. perspective. 2011 , 157, 307-37	1
208	The hematopoietic growth factors in acute leukemia: a European perspective. 2011 , 157, 339-62	3
207	Hematopoietic growth factors in older cancer patients. 2011 , 157, 383-402	4
206	The myeloid growth factors. 2011 , 157, 109-25	1
205	Mucosal Barrier Injury and Infections. 2011 , 167-173	4
204	Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors. 2012 , 409-420	1
203	Practice Guidelines for the Use of rHuG-CSF in an Oncology Setting. 2012 , 109-149	2
202	Diffuse Large B-Cell Lymphomas in Older Adults. 2020 , 583-612	1
201	Critical Illness Stress-induced Immune Suppression. 2007 , 217-228	4
200	Disorders of Blood Cell Production in Clinical Oncology. 2008 , 677-692	2
199	Infection in the Patient with Cancer. 2008 , 717-737	2
198	Immunomodulators. 2010 , 611-623	1
197	Total Body Irradiation. 2010 , 279-302	1
196	Doxorubicin and Cisplatin Regimen for High-Grade Osteosarcoma or Malignant Fibrous Histiocytoma (MFH) of the Bone. 2007 , 42, 605-610	1
195	A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. 2013 , 8, e53252	13
194	Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: a single arm intervention study. 2014 , 9, e115879	9

193	Whom to treat? Factors associated with chemotherapy recommendations and outcomes among patients with NHL at the Uganda Cancer Institute. 2018 , 13, e0191967	1
192	1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. 2015 , 6, 410-415	3
191	Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. 2018 , 9, 18970-18984	6
190	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. 2018 , 9, 27789-27796	6
189	Chemotherapy in the elderly. 2007 , 3, 165-175	2
188	Bacterial Infections in Cancer Patients. 2008 , 1-25	1
187	Canadian supportive care recommendations for the management of neutropenia in patients with cancer. 2008 , 15, 9-23	18
186	Physiological aging in older adults with cancer: implications for treatment decision making and toxicity management. 2010 , 36, 26-37; quiz 38-9	5
185	Treatment of acute radiation injuries. 2013 , 133, 2164-6	1
184	Geriatric oncology: an overview of progresses and challenges. 2010 , 42, 61-8	39
183	Optimal management of patients receiving cabazitaxel-based chemotherapy. 2013 , 7, S18-24	5
182	Revisiting use of growth factors in myelodysplastic syndromes. 2012 , 13, 1081-91	10
181	Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting. 2012 , 13, 4623-6	5
180	Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration- resistant prostate cancer. 2014 , 15, 3443-6	6
179	Critical Illness Stress-induced Immune Suppression. 2007 , 217-228	
178	Paclitaxel and Gemcitabine (PG) for Advanced Breast Cancer. 2007 , 42, 510-516	
177	Hematological and Oncological Emergencies. 2008 , 781-801	
176	Prise en charge de l'iatrogénie liée à la chimiothérapie anticancéreuse. 2008 , 671-719	1

- 175 A Retrospective Study on the Use of G-CSF in Paclitaxel plus Carboplatin Combination Chemotherapy for the Treatment of Advanced Lung Cancer. **2008**, 34, 361-365
- 174 Hematopoietic Growth Factors and Cytokines. **2008**, 605-619 1
- 173 Therapeutische Grundlagen in der gynäkologischen Onkologie. **2008**, 197-271
- 172 SMALL CELL LUNG CANCER. **2008**, 825-840
- 171 Usefulness of Cancer Chemotherapy Adverse Effects Manual in Department of Urology, Okayama University Hospital. **2008**, 34, 962-971
- 170 Supportive Care for Older Cancer Patients. **2008**, 1-34
- 169 Myeloid Growth Factors. **2008**, 1-29
- 168 Neutropenia and Its Complications. **2008**, 1-19
- 167 Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide Regimen for Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) of Bone. **2008**, 43, 367-372
- 166 Supportive Care of the Older Cancer Patient. **2009**, 249-268
- 165 Docetaxel and Cyclophosphamide Regimen in the Treatment of Breast Cancer. **2008**, 43, 710-714
- 164 Neutropenia.
- 163 Immunity to Fungi.
- 162 Pré-requis avant la mise en route d'une chimiothérapie pour cancer colorectal. **2009**, 30-46
- 161 Complications of Chemotherapy. **2009**, 1353-1360
- 160 Therapie und Prophylaxe der febrilen Neutropenie mit koloniestimulierenden Faktoren (CSF). **2009**, 63-65
- 159 Therapie und Prophylaxe von Infektionen bei Neutropenie. **2009**, 57-62
- 158 Notfälle in der internistischen Onkologie und Hämatologie. **2009**, 945-970

- 157 Infectious Diseases in Pediatric Cancer. **2009**, 1099-1120 ○
- 156 OPPORTUNISTIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. **2009**, 1037-1047
- 155 Evaluation of G-CSF Use in Breast Cancer Patients Undergoing FEC100 Therapy. **2009**, 35, 31-36 ○
- 154 Prophylaxis. **2009**, 259-308
- 153 Combining Platinums in Gastric Cancer. **2009**, 251-270
- 152 Modulation of Immune Function. **2009**, 234-258
- 151 Modern Supportive Care in Oncology. **2009**, 1373-1377
- 150 Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation.
- 149 Antibiotics plus colony stimulating factors (CSFs) versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation.
- 148 Invasive Aspergillosis. **2009**, 293-307
- 147 Adjuvant Chemotherapy. **2010**, 249-262
- 146 Infections in the Immunocompromised Host. **2010**, 361-375
- 145 Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen. **2009**, 44, 1072-1081
- 144 Poursuite des traitements spécifiques et prise en charge des symptômes en situation métastatique : quelle prise de risque en cas de neutrophie ?. **2010**, 285-290
- 143 Therapie und Prophylaxe der Neutropenie mit koloniestimulierenden Faktoren (CSF). **2010**, 81-84
- 142 Infections and Cancer. **2010**, 195-202
- 141 Prophylaxe und Therapie von Infektionen bei Neutropenie. **2010**, 73-79
- 140 The economics of the hematopoietic growth factors. **2011**, 157, 403-18

139 Infections in the neutropenic cancer patient. **2010**, 804-820

138 Liposomal Doxorubicin and Bortezomib for Relapsed or Refractory Multiple Myeloma. **2010**, 45, 201-223

137 Fungal Infections in Neutropenic Patients. **2011**, 465-496

136 Hematologic Support of the Patient with Malignancy. **2011**, 381-405

135 Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience. **2010**, 8, 213-9

1

134 Immunotherapy for Difficult-to-Treat Invasive Fungal Diseases. **2011**, 331-339

133 Hematological Changes, Anemia, and Bleeding in Older Persons. **2011**, 69-82

132 A5 Cytokines. **2011**, 59-80

131 Hämologische und onkologische Erkrankungen. **2011**, 607-718

130 Urgences hémalogiques et oncologiques. **2011**, 799-819

129 Chemotherapie und gezielte Tumorthapie. **2011**, 195-217

128 Antibacterial, Antifungal, and Antiviral Prophylaxis in High-Risk Cancer and Stem Cell Transplant Population. **2011**, 521-531

127 Tumori nell'anziano. **2011**, 281-291

126 Tossicit  acute da trattamento: terapia di supporto. **2011**, 227-236

125 Neutropenia. **2011**, 2506-2509

124 Acute Lymphoblastic Leukemia. 228-243

123 Antibiotics plus colony stimulating factors (CSFs) versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation.

122 Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation.

- 121 Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI) plus Bevacizumab for Metastatic Colorectal Cancer. **2011**, 46, 748-754 1
- 120 Supportive Care. **2012**, 121-141
- 119 Use of rHuG-CSF in New Chemotherapy Strategies. **2012**, 225-247
- 118 Management of Bacterial Infectious Complications in Cancer Patients. **2012**, 259-273
- 117 Use of rHuG-CSF in Infectious Diseases. **2012**, 319-333
- 116 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 115 Chemotherapy-Induced Myelosuppression in the Elderly. **2012**, 115-125
- 114 Fever and Granulocytopenia. **2012**, 567-573.e4
- 113 Total Body Irradiation. **2012**, 345-360 0
- 112 A safety profile of sequential therapy for unresectable head and neck cancer: A retrospective analysis in a single institution. **2012**, 38, 374-379
- 111 Cancer and Ageing. 1317-1331
- 110 Effective Communication with Older Cancer Patients. **2013**, 169-177
- 109 Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Regimen for Breast Cancer. **2012**, 47, 683-689
- 108 Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoietic stem cell transplantation.
- 107 Prostate Cancer Emergencies. **2013**, 1041-1054
- 106 Blut. **2013**, 230-247
- 105 Hematologic and Coagulation Implications of Neurologic Disease. **2013**, 321-341
- 104 Mammakarzinom. **2013**, 625-705

103 Endoscopy in Hematologic Malignancies. 317-326

102 Alternatives to Allogeneic Transfusion. 800-845

101 Hematopoietic System. **2014**, 623-655

3

100 Prevention of Febrile Neutropenia. **2014**, 13-26

99 A Pharmacocybernetics Approach to Patient Safety. **2014**, 179-197

98 Evaluation of Efficacy and Safety of Sulfamethoxazole/trimethoprim Prophylaxis for the Incidence of Fever during R-CHOP Chemotherapy. **2014**, 40, 78-84

97 Disorders of Blood Cell Production in Clinical Oncology. **2014**, 532-541.e10

96 Myeloid Growth Factors. **2015**, 315-324

95 Bone Marrow and Peripheral Blood Cells Toxicity of a Single 2.0 Gy Cobalt Ionizing Radiation: An Animal Model. **2019**, 29, 195-202

5

94 Immunotherapy. 467-478

93 Risk Stratification in Febrile Neutropenic Patients. **2015**, 137-152

92 Hematopoietic Growth Factors. **2015**, 247-260

91 Cellular Therapies in Post-radiation Syndrome. **2015**, 629-636

90 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2015**, 1-31

89 Encyclopedia of Cancer. **2015**, 1-4

88 Supporting the patient. **2015**, 129-148

87 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

86 Management der Neutropenie bei Tumorpatienten. **2015**, 1-3

- 85 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. 284-294
- 84 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2016**, 409-430
- 83 Cabazitaxel For the Treatment of Prostate Cancer. **2016**, 187-214
- 82 Second Malignancies. **2016**, 235-237
- 81 A Pharmacocybernetics Approach to Patient Safety. **2016**, 1445-1464
- 80 A Pharmacocybernetics Approach to Patient Safety. **2017**, 1291-1310
- 79 Hematological Side Effects. **2017**, 191-206
- 78 Encyclopedia of Cancer. **2017**, 3085-3088
- 77 Diffuse Large B-Cell Lymphomas in Older Adults. **2018**, 1-31
- 76 Cancer in Older Adults. **2018**, 1-21
- 75 Supportive Care in Paediatric Oncology. **2018**, 89-107
- 74 Automation In High Throughput/Content Screening For Cancer Stem Cell Drug Discovery. **2018**,
- 73 Cost-Utility Analysis of Pegfilgrastim and Pegteograstim in Patients with Breast Cancer using Doxorubicin and Cyclophosphamide. **2018**, 35, 409-417
- 72 Chemotherapie, gezielte Tumorthherapie, Immuntherapie. **2019**, 203-226
- 71 Investigation of the Adverse Events and Efficacy of Docetaxel+Cisplatin+5-Fluorouracil in Patients with Head and Neck Squamous Cell Carcinoma. **2018**, 121, 1486-1492
- 70 Prophylaxe und Therapie von Komplikationen der systemischen Tumorthherapie. **2019**, 1-18
- 69 Effectiveness of filgrastim and polyethylene glycol-filgrastim in the treatment of postchemotherapy neutropenia in children: Phase I clinical trial. **2019**, 40, 101-104
- 68 Principles of Chemotherapy in Older Adults. **2019**, 1-20

67	Cancer in Older Adults. 2020 , 189-209		
66	Hämatologische und onkologische Notfälle. 2020 , 152-165		
65	Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients. 2020 , 5, 120-127		1
64	Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy. 2020 , 23, 521-532		1
63	Critically Ill Pediatric Oncology Patients: What the Intensivist Needs to Know? Pediatric Critical Care Medicine. 2020 , 24, 1256-1263		1
62	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. 2020 , B-1-B30-3		
61	Principles of Chemotherapy in Older Adults. 2020 , 861-880		
60	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: A single-center retrospective study.		
59	Efficacy of Naproxen and Loratadine Versus Acetaminophen and Loratadine on Relief of Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF)-Induced Bone Pain During Chemotherapy; A Randomized Controlled Trial. 2020 , 13,		
58	Clinical and Therapeutic Implications of Epstein-Barr Virus in HIV-Related Lymphomas. <i>Cancers</i> , 2021 , 13,	6.6	2
57	Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson's Disease. 2021 , 13, 769506		2
56	Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 1	3.5	4
55	Meta-analysis of Pegfilgrastim over Filgrastim in the Treatment of Chemotherapy-induced Neutropenia. 2020 , 28, 71-80		0
54	Chemotherapie und gezielte Tumorthherapie. 2014 , 207-230		0
53	Supportive Treatment. 2008 , 204-292		
52	Chemotherapie und gezielte Tumorthherapie. 2009 , 201-221		
51	Allgemeine onkologische Chemotherapie. 2014 , 689-709		0
50	Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy. <i>Journal of Modern Oncology</i> , 2020 , 22, 133-141	0.3	2

49	Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. <i>Blood Transfusion</i> , 2015 , 13, 478-83	3.6	14
48	Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. <i>Journal of Medicine and Life</i> , 2010 , 3, 96-9	1.5	2
47	Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC. <i>Journal of Thoracic Disease</i> , 2009 , 1, 55-62	2.6	3
46	Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2011 , 2, 61-3	2.8	3
45	Supportive therapy in medical therapy of head and neck tumors. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2012 , 11, Doc01		
44	<i>Pseudomonas aeruginosa</i> endocarditis in acute myeloid leukemia: a rare complication. <i>International Journal of Biomedical Science</i> , 2008 , 4, 330-2		
43	Oncological emergencies associated with gastrointestinal tumors. <i>Annals of Gastroenterology</i> , 2015 , 28, 426-30	2.2	1
42	Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2016 , 10, 85-91	0.5	2
41	Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. <i>P and T</i> , 2016 , 41, 765-768	1.4	21
40	Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. <i>European Urology</i> , 2021 ,	10.2	2
39	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
38	Chemotherapy Side-Effects: Not All DNA Damage Is Equal.. <i>Cancers</i> , 2022 , 14,	6.6	6
37	Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy. <i>Journal of Chemotherapy</i> , 2021 , 1-9	2.3	
36	Radiotherapy and Systemic Anti-Cancer Treatment in Older Adults with Cancer and Frailty. 2022 , 235-264		0
35	Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy.. <i>Scientific Reports</i> , 2022 , 12, 2483	4.9	1
34	Feasibility of cabazitaxel in octogenarian prostate cancer patients. <i>Current Urology</i> , 2022 , Publish Ahead of Print,	1.7	
33	Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.. <i>Oncologist</i> , 2022 ,	5.7	
32	Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.. <i>JCO Global Oncology</i> , 2022 , 8, e2100276	3.7	

31	Bone Marrow Harbors a Unique Population of Dendritic Cells with the Potential to Boost Neutrophil Formation upon Exposure to Fungal Antigen.. <i>Cells</i> , 2021 , 11,	7.9	0
30	Management of acute myeloid leukemia. 26-42		
29	Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 ,	3.5	
28	Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 777602	5.3	0
27	[G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer : Guidelines on supportive treatment part 1].. <i>Der Urologe</i> , 2022 , 61, 537		
26	Effectiveness and safety of empegfilgrastim (Extimia [®] , BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study. <i>Journal of Modern Oncology</i> , 2022 , 21, 88-98	0.3	
25	Neutropenic Enterocolitis as a Complication of Autologous Stem Cell Transplant in Patients With Multiple Myeloma: A Case Series. <i>Cureus</i> , 2022 ,	1.2	1
24	Burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia. <i>SAGE Open Medicine</i> , 2022 , 10, 205031212210982	2.4	
23	Progress of Clinical Application of Pegylated Recombinant Human Granulocyte-Colony Stimulating Factors and Its Effect on Immune Status. <i>Advances in Clinical Medicine</i> , 2022 , 12, 4916-4923	0	
22	Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). <i>Supportive Care in Cancer</i> ,	3.9	1
21	S3-Leitlinie zum exokrinen Pankreaskarzinom âKurzversion 2.0 âDezember 2021, AWMF-Registernummer: 032/010OL. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, 991-1037	1.6	0
20	G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung. <i>Best Practice Onkologie</i> ,	0	
19	G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. <i>Expert Review of Hematology</i> , 1-15	2.8	0
18	Granulocyte Colony-Stimulating Factor Utilization and Prescribing Patterns in Cancer Patients: A Single Institution Experience of a Saudi Cancer Center. <i>Cureus</i> , 2022 ,	1.2	
17	A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe.		0
16	Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. 2022 , 12,		1
15	A systemic review of taxanes and their side effects in metastatic breast cancer. 12,		0
14	Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing. 2022 , 5, e2238191		0

- 13 A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia. ○
- 12 S3-Leitlinie zum exokrinen Pankreaskarzinom –Langversion 2.0 –Dezember 2021 – AWMF-Registernummer: 032/010OL. **2022**, 60, e812-e909 ○
- 11 Risk Factors and Infectious Agents in Children With Cancer. **2023**, 596-604.e4 ○
- 10 Prospective Audit of Febrile Neutropenia Management at a Tertiary University Hospital in Singapore. **2010**, 39, 453-459 2
- 9 Prospective Audit of Post-chemotherapy Febrile Neutropenia in Patients with Solid Cancer and Lymphoma in Two Singaporean Cancer Centres. **2012**, 41, 287-293 ○
- 8 A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest. ○
- 7 G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study. **2023**, 35, 100690 ○
- 6 Mycosis in the Philippines: Epidemiology, clinical presentation, diagnostics and interventions. **2023**, 213-233 ○
- 5 Introduction to Oncologic Emergencies. **2013**, 1665-1678.e1 ○
- 4 Neutropenia febbrile in Pronto Soccorso. **2023**, 27, 1-16 ○
- 3 Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. **2023**, 31, ○
- 2 Urothelkarzinom der Nieren und Harnleiter: Therapie. **2022**, 1-15 ○
- 1 Two decades of pegfilgrastim: what have we learned? Where do we go from here?. 1-12 ○